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ABSTRACT 
The 5-HT3A receptor is a cys-loop ligand gated ion channel re-emerging as an attractive target 
in irritable bowel syndrome (IBS), which currently affects 5-10% of the global population. At 
present, IBS therapies involve the complete blockade of the 5-HT3A receptor by orthosteric 
antagonists, which leads to complications such as severe constipation and ischaemic colitis. 
Allosteric modulation could bypass such side effects, as receptor function relies upon the 
endogenous neurotransmitter to retain physiological control. Here, we investigate the 
structure and function of the 5-HT3A receptor allosteric binding site by the identification of 
novel allosteric compounds and the generation of an α7/5-HT3A chimeric receptor. 
Intracellular calcium assays and competitive radioligand binding experiments indicated that 
the halogenated indole derivatives, 5-chloroindole (5-Cl) (Newman et al., 2013) and 5-
(trifluoromethyl)indole (5-TFMI) are positive allosteric modulators (PAM) of the 5-HT3A 
receptor; however 5-TFMI also displayed a degree of orthosteric binding. The structural 
analogues, 5-bromoindazole (5-BI) and 5-bromo-benzimidazole (5-BBI) exhibited contrasting 
effects, by potentiating and decreasing 5-HT-evoked responses, respectively. Further studies 
suggested some orthosteric binding by 5-BI and 5-BBI at high concentrations. The allosteric 
binding site for 5-Cl was previously located in the N-terminus of the mouse 5-HT3A receptor. 
To identify the site in the human receptor, we attempted to construct a human chimeric 
α7V2015-HT3A receptor to allow further investigation into this question. Our data suggest 
these halogenated indoles are allosteric compounds and, when studied in combination with 
the α7V2015-HT3A chimera, could identify the required core structure of high affinity 
compounds needed for negative allosteric modulation in the treatment of IBS. 
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CHAPTER 1: INTRODUCTION 
 
1.1. The Serotonergic System 
5-hydroxytryptamine (5-HT), or serotonin, is a monoamine neurotransmitter involved in 
multiple signalling pathways throughout various physiological systems. 5-HT was initially 
identified as a potent vasoconstrictor in serum (Rapport  et al, 1947) and the notion of 5-HT 
binding to specific receptors in the nervous system and on smooth muscle was introduced in 
the 1950s, by Gaddum et al (1953).  
 
1.2. Distribution of 5-HT 
1.2.1. Blood 
5-HT was initially identified in the 1940s as a potent vasoconstrictor originating from 
platelets in the serum (Rapport, 1947). Platelets accumulate 5-HT by active uptake and release 
it when aggregated at sites of tissue damage, possibly to help recruit further platelets 
(Hardisty (1955), Vanhoutte (1991)).  
1.2.2. CNS  
5-HT in the brain is synthesised from L-tryptophan and stored in vesicles in serotonergic 
neurons located mainly in the raphe nuclei of the midbrain. These neurons project to almost 
every region of the brain, including the hippocampus, cerebellum, midbrain, cortex, as well as 
the spinal cord (Murphy, 1998). 5-HT is released from axon terminals, and signalling is 
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terminated by reuptake into the presynaptic terminal by an energy-dependent transporter 
molecule, the serotonin transporter (SERT). Due to release of 5-HT in almost every region of 
the CNS, the serotonergic system is involved in regulating a variety of functions such as: 
blood pressure, body temperature, appetite, hormone release and emotional behaviour. 
Imbalances of 5-HT signalling can therefore disrupt these functions and play a role in the 
pathophysiology of hypertension, hormonal dysfunction, anxiety and depression.  
1.2.3. Periphery 
Approximately 90-95% of all 5-HT is stored within and secreted by enterochromaffin cells in 
the gut. Epithelial enterochromaffin cells act as sensory transducers that activate the mucosal 
processes of both intrinsic and extrinsic primary afferent neurones through their release of 5-
HT. The primary afferent neurons are present in both the submucosal and myenteric plexus, 
and stimulate secretory and peristaltic reflexes when activated (Gershon and Tack, 2007). As 
a neurotransmitter in the gut, 5-HT can also stimulate cholinergic neurons to release 
acetylcholine resulting in smooth muscle contraction, or it can stimulate inhibitory neurons to 
release nitric oxide, mediating smooth muscle relaxation (Sikander et al., 2009). 
 
1.3. Pathophysiology of the Serotonergic System 
Associated with its widespread distribution, 5-HT is involved in regulating a range of central 
and peripheral functions; therefore misregulation of 5-HT signalling can have multiple 
adverse effects throughout the body. 5-HT has been found to play a role in anxiety, 
depression, addiction and emesis by various mechanisms including excessive release of 5-HT, 
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lack of reuptake by the serotonin transporter (SERT) or lack of metabolism to terminate 
signalling [for reviews see (Barnes and Sharp, 1999, Filip and Bader, 2009)].  
In the periphery, 5-HT has been shown to mediate some of the symptoms of irritable bowel 
syndrome (IBS). Increased postprandial plasma 5-HT levels were detected in patients with 
IBS, which correlates to colonic motility (Houghton et al., 2007) resulting in diarrhoea. 
Mouse knock-out models of SERT exhibit increased colonic motility, watery stools and 
alternating patterns of constipation and diarrhea, similar to the symptoms of IBS (Chen et al., 
2001).   
 
1.4. Receptor Classification 
There are 14 known genetically and pharmacologically distinct 5-HT receptors classed into 7 
families (5-HT1 to 5-HT7) (Langer et al., 1980, Hoyer et al., 1994, Barnes and Sharp, 1999) 
Most of the 5-HT receptors have been identified as seven transmembrane domain G protein 
coupled receptors, except for the 5-HT3 receptors, which are cys-loop ligand-gated ion 
channels.  
1.4.1. The 5-HT1 Receptor Family 
The 5-HT1 receptor family is comprised of five receptor subtypes: 5-HT1A, 5-HT1B, 5-HT1D, 
5-ht1E and 5-ht1F. The latter two subtypes are named in lower case as their presence has not 
yet been determined in native tissues. These receptors are seven transmembrane spanning 
proteins negatively coupled to adenylate cyclase via the αi G protein.  
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1.4.1.1. 5-HT1A Receptor 
The gene coding for the human 5-HT1A receptor is localised on chromosome 5 (5q11.2-q13) 
and codes for a seven transmembrane spanning protein with sites for glycosylation and 
phosphorylation.  
Distribution of this receptor has been determined by autoradiography using a range of 
radioligands such as [3H]-5-HT and [3H]-8-OH-DPAT (Pazos and Palacios, 1985). 5-HT1A 
receptors are mainly found in limbic brain areas such as the hippocampus (postsynaptically), 
lateral septum, cortex and mesencephalic raphe nuclei (presynaptically).  
The 5-HT1A receptor exerts inhibitory actions by coupling to the αi G protein in rat and guinea 
pig hippocampus. In electrophysiological studies, 5-HT1A receptor activation causes neuronal 
hyperpolarisation, exerted by potassium (K+) channel opening. Activation of these receptors 
mediates various physiological and behavioural effects, such as neuroendocrine regulation of 
adrenocorticotrophic hormone (ACTH) (Jørgensen et al., 2001). In murine 5-HT1A receptor 
knock-out models, mice showed increased levels of anxiety in the elevated plus maze and 
decreased baseline immobility in tail suspension tests (Heisler et al., 1998). Presynaptic 
5HT1A agonists, such as buspirone, are being used for the treatment of anxiety and depression 
by attenuating 5-HT neurotransmission in the raphe nuclei (Tunnicliff, 1991). 
1.4.1.2. 5-HT1B Receptor 
The 5-HT1B receptor was found to be pharmacologically different to the 5-HT1A receptor, 
with a lower affinity for [3H]-8-OH-DPAT in autoradiographic studies (Middlemiss and 
Fozard, 1983). The gene encoding for the 5-HT1B receptor is located on chromosome 6q13 
(Saudou and Hen, 1994). 
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5-HT1B receptors are expressed in the CNS, particularly in basal ganglia, striatum and frontal 
cortex. They are thought to be presynaptic autoreceptors and potentially as heteroreceptors 
modulating the release of other neurotransmitters such as acetylcholine, glutamate and 
dopamine (Hoyer et al., 2002, Pauwels, 1997). These receptors are also found on cerebral 
arteries and other vascular tissues, and are thought to play a role in migraines. Agonists such 
as sumatriptan have been developed to treat acute migraines.  
1.4.1.3. 5-HT1D Receptor 
The gene coding for the 5-HT1D receptor is located on chromosome 1p34.3–p36.3. This 
receptor possesses 63% structural homology with the 5-HT1B receptor, and was once thought 
to be species a homologue (Hoyer and Middlemiss, 1989). Novel 5-HT1B receptor ligands 
have suggested the presence of 5-HT1D autoreceptors in the dorsal raphe nuclei (Roberts et al., 
2001), and also in the human heart. PNU 109291, a selective 5-HT1D agonist, has been shown 
to suppress meningeal neurogenic inflammation and trigeminal nociception in guinea pig 
models, suggesting this receptor could be a potential therapeutic target for migraine (Cutrer et 
al., 1999). 
1.4.1.4. 5-ht1E Receptor 
The gene for the 5-ht1E receptor has been located on human chromosome 6q14-q15 (Levy et 
al., 1994). Radioligand binding studies revealed a low affinity binding site with different 
pharmacology to the 5-HT1D receptor, suggesting a novel 5-HT receptor. However, due to the 
lack of specific radioligands to the 5-ht1E receptor, distribution, pharmacology and 
physiological function of this receptor have not been characterised in humans. 
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1.4.1.5. 5-ht1F Receptor 
The human 5-ht1F receptor gene is located on chromosome 3q11 (Saudou and Hen, 1994). 5-
ht1F mRNA was first localised in the mouse and guinea pig brain using in situ hybridisation in 
the hippocampus (CA1–CA3 cell layers), cortex and dorsal raphe nucleus (Bruinvels et al., 
1994). Similarly to the 5-ht1E receptor, activation of the native human 5-ht1F receptor has 
unknown effects, but based on the anatomical location; it has been hypothesised that they 
could play a role in visual and cognitive function and as 5-HT autoreceptors.  
 
1.4.2. The 5-HT2 Receptor Family 
There are three receptor subtypes in the 5-HT2 receptor family: 5-HT2A, 5-HT2B and 5-HT2C. 
These receptors are seven transmembrane-spanning proteins, all positively coupled to 
phospholipase C and mobilise intracellular calcium via Gq/11.  
1.4.2.1. 5-HT2A Receptor 
The 5-HT2A receptor gene is located on human chromosome 13q14-q21 (Chen et al., 1992). 
Autoradiography, in situ hybridisation and immunocytochemistry have localised 5-HT2A 
receptors to many forebrain regions, but particularly cortical areas (neocortex, entorhinal and 
pyriform cortex, claustrum), caudate nucleus, nucleus accumbens, olfactory tubercle and 
hippocampus (Lopez-Gimenez et al., 1997). There is an interest in targeting the 5-HT2A 
receptor with antipsychotic drugs due to it playing a role in hallucinogenic mechanisms 
(Glennon, 1990). It has also been found to mediate responses such as hyperthermia (Gudelsky 
et al., 1986) and neuroendocrine responses. 
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1.4.2.2. 5-HT2B Receptor 
The human 5-HT2B receptor gene is located at chromosomal position 2q36.3–2q37.1. 5-HT2B 
mRNA transcripts have been detected in human liver and kidney and in low levels in the brain 
(Bonhaus et al., 1995). Little is known about the function of the native 5-HT2B receptor, 
although the 5-HT2B receptor agonist BW 723C86 has been shown to have anxiolytic effect in 
rat models (Kennett et al., 1996).  
1.4.2.3. 5-HT2C Receptor 
The 5-HT2C receptor gene is X-linked, located on chromosome Xq24 (Xie et al., 1996). There 
is little evidence to suggest the 5-HT2C receptor is expressed in other tissues than the brain. 
Very high levels of 5-HT2C binding sites were detected in the choroid plexus (Conn et al., 
1986), but also in areas of the cortex, limbic system, and basal ganglia (Sheldon and 
Aghajanian, 1991). Activation of 5-HT2C receptors mediates a variety of behavioural 
responses such as hypolocomotion, hypophagia and anxiety, and are also possibly implicated 
in the pathophysiology of schizophrenia and depression (Koek et al., 1992). 
 
1.4.3. 5-HT4 Receptor 
The gene encoding for the 5-HT4 receptor was mapped to chromosome 5q31-33 (Claeysen et 
al., 1997), and several isoforms and splice variants have been identified. 5-HT4 receptors are 
7-transmembrane spanning proteins positively coupled to adenylate cyclase. The receptors are 
distributed throughout tissues such as the gut (Blondel et al., 1998), where they mediate 
peristalsis and secretory responses, in cardiac atria, where they mediate tachycardia in the 
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right atria and positive inotropic effects in the left atria; and the brain, enhancing cognition 
(Mialet et al., 2000). 
1.4.4. 5-HT5 Receptors 
The 5-HT5 receptors are the least well understood receptors of all the subtypes. Two subtypes 
of the receptor (5-ht5A and 5-ht5B) have been found in rodents and the genes encoding the 
human subtypes have been located on chromosomes 7q36.1 (Schanen et al., 1996)and 2q11-
13  respectively, although the gene encoding the 5-ht5B subunit failed to encode a functional 
receptor (Grailhe et al., 2001). Recently, Goodfellow et al. (2012) characterised functional 5-
HT5A receptors in the rodent prefrontal cortex, by electrophysiology. They showed activation 
of 5-HT5A receptors produces small inwardly-rectifying K+ currents, and knock-out of the 
htr5A gene caused a compensatory increase in 5-HT1A receptor expression, suggesting a 
possible role in anxiety and depression modulation.  
1.4.5. 5-HT6 Receptors 
The gene coding for the 5-ht6 receptor sequence has been mapped to chromosome 1p35-36 
(Kohen et al., 1996), and found to positively couple to adenylyl cyclase via Gs. Human 5-ht6 
mRNA has been located mostly postsynaptically throughout the central nervous system (Ruat 
et al., 1993), though low levels of mRNA have also been detected in the stomach and adrenal 
glands (Monsma et al., 1993). Antipsychotic drugs such as clozapine and olanzapine, and 
antidepressants such as clomipramine and amitriptyline act as 5-ht6 antagonists suggesting 
their involvement in the clinical efficacy and/or the side effects associated with these drugs 
(Monsma et al., 1993, Kohen et al., 1996). Sleight et al. (1998) demonstrated an interaction 
between 5-ht6 receptors and the central cholinergic system, as antagonists appear to increase 
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cholinergic transmission, with positive effects on learning and memory (Meneses et al., 
2007), suggesting a potential target for cognitive disorders such as Alzheimer’s disease.  
1.4.6. 5-HT7 Receptors  
The gene encoding the 5-HT7 receptor sequence has been mapped to chromosome 10q21-24 
(Gelernter et al., 1995). Functional studies have shown that this receptor positively couples to 
adenylyl cyclase via Gs, is extensively distributed throughout vascular tissue and is 
responsible for the vasodilator in response to 5-HT in anaesthetised animals (Martin and 
Humphrey, 1994). It is also expressed in non-vascular smooth muscle and the CNS (Carter et 
al., 1995, Stowe and Barnes, 1998). Centrally, the 5-HT7 receptor is thought to mediate a 
variety of functions such as the regulation of circadian rhythms (Lovenberg et al., 1993), 
manifestation of seizures (Bourson et al., 1997) and possible involvement in depressive 
behaviours (Guscott et al., 2005).  
 
1.5. The 5-HT3 Receptor Family 
The 5-HT3 receptors are the distinct from the other 5-HT receptors as they belong to the cys-
loop ligand gated ion channel superfamily, which encompasses receptors such as the nicotinic 
acetylcholine receptors and GABAA receptors.  They were originally discovered in the ileum 
and named M receptors by Gaddum and Picarelli (1957), due to their being blocked by 
morphine. A reclassification of serotonin receptors renamed the M receptor to 5-HT3 (Bradley 
et al., 1986). Selective 5-HT3 antagonists such as GR38032F (ondansetron) and BRL43694 
(granisetron) revealed an anti-emetic effect of these compound and also helped in identifying 
the widespread presence of 5-HT3 binding sites in the PNS (Miner and Sanger, 1986, Fozard, 
10 
 
1984). The presence of central 5-HT3 binding sites was established using radioligand binding 
(Kilpatrick et al., 1987), and single channel studies confirmed the 5-HT3 receptors were 
ligand-gated ion channels (Derkach et al., 1989).  
 
1.5.1. 5-HT3 Receptor Structure 
The functional 5-HT3 receptor is a pentameric formation of either identical or non-identical 
subunits, which surround a central pore. Each subunit is formed of a large extracellular N-
terminus, which contains the ligand binding site, 4 membrane-spanning regions termed M1-
M4, which allow ion selectivity, a large intracellular loop between M3 and M4 and a small 
extracellular C-terminus. Several subunits have been identified: 5-HT3A and 5-HT3B, 5-HT3C, 
5-HT3D and 5-HT3E. Only the 5-HT3A subunit is able to form functional homomeric receptors, 
whilst the others appear to require at least one 5-HT3A subunit to form functional heteromeric 
receptors (Niesler et al., 2008). Figure 1 shows the diagrammatic representation of the 
structure of the 5-HT3 receptors.  
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Figure 1: Top: Diagram of the structure of one subunit of the 5-HT3 receptor as seen parallel to the 
plane of the membrane. The extracellular N-terminus, C-terminus and its loops are depicted by the 
letters N, C and A-F, respectively. 4 transmembrane domains are labelled M1-M4, with a large 
intracellular loop joining the M3 and M4 domains. Bottom left: Diagram of the structure of the 
pentameric 5-HT3 receptor from an extracellular view, perpendicular to the plane of the membrane 
(bottom left). Each large grey circle depicts a single subunit of the 5-HT3 receptor, containing 4 
smaller circles; the transmembrane domains M1-M4.  The M2 domains are shown in white, lining the 
channel pore.  (Thompson and Lummis, 2007) 
 
Recently, Hassaine et al. (2014) succeeded in obtaining the crystal structure of the mouse 5-
HT3A receptor using VHH15 molecules, termed ‘nanobodies’ (single chain antibodies) as 
crystallisation chaperones. They established the structure of the murine 5-HT3A receptor as 
‘bullet-shaped’ with five subunits arranged symmetrically around a central ion channel, 
perpendicular to the membrane plane, as shown in figure 2.  
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Figure 2: Crystal structure of the mouse 5-HT3 receptor in complex with VHH15 nanobodies. a: 
cartoon representation of the receptor parallell to the plane of the membrane. The VHH15 nanobodies 
are shown in light green and each subunit is represented by a different colour. b : View from above of 
the receptor forming the channel pore. All VHH15 molecules (light green) are visible in this plane at 
the interfaces between subunits. (Hassaine et al., 2014) 
 
1.5.2. 5-HT3A Receptor 
The 5-HT3A subunit was originally identified by isolation from a neuroblastoma cell line 
expressing high levels of the functional 5-HT3 receptor (Lambert et al., 1989). The subunits 
assemble to form functional homopentamers in mammalian cell hosts. The HTR3A gene 
coding for this subunit is mapped to chromosome 11, and codes for a protein 478 to 490 
amino acids in length. Distribution of the 5-HT3A receptor is widespread in the CNS 
(Kilpatrick et al., 1987), peripheral and sensory ganglia and gastrointestinal tissues (Morales 
et al., 1998). 
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1.5.3. 5-HT3AB Receptor 
The 5-HT3B subunit was isolated in 1999 by screening human genomic sequence data (Davies 
et al., 1999). The 5-HT3B subunit requires co-expression with the 5-HT3A subunit for cell 
surface expression of a functional 5-HT3AB heteromer with distinct biophysical properties. 
The gene coding for the 5-HT3B subunit is also located on chromosome 11, and produces a 
436 amino acid sequence, sharing 41% amino acid sequence identity with the 5-HT3A subunit 
(Davies et al., 1999). Atomic force microscopy by Barrera et al. (2005) revealed the 
heteromeric receptor contains two 5-HT3A and three 5-HT3B subunits assembled in the order 
B-B-A-B-A. This stoichiometry has however been widely discussed in further publications 
(Connolly, 2011) due to the fact that Thomson et al. (2011) revealed that A-A subunit 
interfaces contributed to the ligand binding site and B-B interfaces did not. Barrera et al. 
(2005) also included endoplasmic reticulum-retained receptors in their study, including the 
possibility of non-functional receptors. Other subunit orders such as B-B-B-A-A or even 
different stoichiometries with (3A)3 and (3B)2 have been suggested with the orders A-A-B-A-
B or A-A-B-A-B to allow for A-A interfaces.  
 
1.5.4. 5-HT3C, 5-HTD & 5-HTE Receptors 
The three additional 5-HT3 receptor subunits are mapped on chromosome 3q27 (Niesler et al., 
2008). The 5-HT3C and 5-HT3E subunits possess 36% and 39% amino acid sequence identity 
with the 5-HT3A subunit, respectively. None of the subunits, when singly expressed in a 
mammalian cell host, traffic to the cell surface or produce ligand binding domains and require 
co-expression of the 5-HT3A subunit for functional receptor expression at the cell surface. The 
heteromeric receptors do not appear to differ greatly in pharmacological profiles and their 
14 
 
biophysical properties are yet to be tested (Niesler et al., 2007). The 5-HT3D subunit has two 
splice variants, one lacking a large portion of the extracellular N-terminus and the other 
lacking a cys-cys loop (Lummis, 2012), two very important features for functional receptors. 
Their function is generally unknown, but hypothesised to play a role in modifying receptor 
function when co-expressed with other subunits.  
 
1.5.5. The 5-HT3 Receptor Ligand Binding Site 
Previously, the structure and function of the 5-HT3 receptor was based on homology to the 
nicotinic acetylcholine receptor. Strong functional and structural similarities between the 5-
HT3 receptor and the nACh receptor (for review, see Thompson and Lummis (2006)) were 
established by constructing chimeric receptors containing the N-terminus of the α7 nicotinic 
acetylcholine (nACh) receptor  and transmembrane domains of the 5-HT3A receptor. These 
chimeras are activated by acetylcholine (ACh) and retain the channel properties of the 5-HT3A 
receptor (Eiselé et al., 1993). Furthermore, the acetylcholine binding protein (AChBP) was 
found to be homologous to the N-terminus of the nACh receptor. Crystallisation of the 
AChBP bound to nicotinic ligands brought insight into ligand recognition in the nACh 
receptor (Brejc et al., 2001). AChBP was also found to bind 5-HT with low affinity. Based on 
the homology models of the nACh receptors and mutated versions of the AChBP, Kesters et 
al. (2013) were able to locate the ligand binding site on the 5-HT3 receptor at the interface of 
two adjacent subunits in the N-terminus, formed of three loops (A-C) on one principal subunit 
and three β-strands (loops D-F) from the adjacent (complementary) subunit. Only a few 
residues on the loops face the binding pocket and figure 3 below shows those contributing 
residues.  
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Figure 3: Left : Cartoon representation of the orthosteric binding site in the N-terminus, with 
contributing loops represented in different colours. Right : Diagram of the residues lining the 
orthosteric binding site, as well as a sequence alignment for each loop of the murine 5-HT3 
receptor with a human receptor of each subfamily (Hassaine et al., 2014).  
 
X-ray crystallography revealed the orthosteric binding site was formed by the loops A, B and 
C from the principal subunit and portions of loops D, E and G and loop F from the 
complementary subunit (Figure 3, Hassaine et al. (2014)). Loops A, B, D and E appeared 
more internal and connected, and were thought to stabilise the structure of the ligand binding 
site, whereas loops C and F were more peripheral. Based on homology models of nicotinic 
acetylcholine receptors, it is thought loop C changes conformation to contract around 5-HT, 
and extends when bound to granisetron (Kesters et al., 2013). 
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There are also a range of potential specific binding sites for different ligands and modulators 
such as steroids, alcohols, anaesthetics and other small molecules (Davies, 2011).   
 
1.5.6. Known Allosteric Modulators of the 5-HT3 Receptor 
There are numerous known allosteric modulators of the 5-HT3 receptor. Alcohols and volatile 
anaesthetics such as butane are an example of positive allosteric modulators (PAMs). 
Compounds with small molecular volumes (such as butanol and halothane) appeared to 
enhance central 5-HT-evoked currents by stabilising the open state of the channel, without 
affecting 5-HT binding affinity (Davies, 2011). The best characterised positive allosteric 
modulator of the 5-HT3 receptor is 5-hydroxyindole, which has been shown to display both 
allosteric and orthosteric effects (Kooyman et al., 1994), possibly due to its similar structure 
to 5-HT. Some studies showed 5-HI allosteric binding in mouse but not human 5-HT3 
receptors, suggesting species differences in allosteric modulation of the 5-HT3 receptor 
(Gronlien et al., 2010). These species differences in allosteric modulation highlight the need 
for thorough study in human receptors. 5-HI is also a positive allosteric modulator of the 
α7nAChR (Zwart et al., 2002), underlining the need for a more specific research tool to study 
the 5-HT3 allosteric binding site.  
Intravenous anaesthetics such as ketamine have been shown to have non-competitive 
inhibitory effects on 5-HT3 receptor channels at high concentrations. Propofol and 
barbiturates were shown to reduce 5-HT3 receptor evoked currents in mouse neuroblastoma 
N1E-115 cells (Barann et al., 2000), suggesting non-competitive behaviour. Different 
categories of antidepressants (imipramine, fluoxetine and iproniazid) have all been shown to 
inhibit the 5-HT3 receptor by blocking the receptor in the closed state (Choi et al., 2003). 
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Some antidepressants also accelerate desensitisation of the receptor (Fan, 1994). Other 
compounds shown to be allosteric modulators of the 5-HT3 receptor include cannabinoids, 
morphine and divalent cations (Davies, 2011).  These compounds show that allosteric 
modulation of the 5-HT3 receptor is possible but their use is not relevant for targeting 5-HT3 
receptors in the gut, due to their non-specificity. 
There are also some naturally occurring allosteric modulators of the 5-HT3 receptor, including 
ginseng, ginger, quinine and liquorice (Davies, 2011). However, the difficulty in studying 
these compounds lies in the comparison of the concentrations used in vivo in traditional 
medicine with in vitro concentrations.  
 
1.5.7. Ion Selection 
The 5-HT3 receptor is permeable to cations such as sodium (Na+), potassium (K+) and also 
calcium (Ca2+). The channel pore is lined with five M2 transmembrane domains, which 
determine ion selectivity. Hassaine et al. (2014) demonstrated the importance of the negative 
charge at position D105, which is conserved in nAChRs; as well as other charged residues in 
the channel pore (R14, D17, K24, K25, D91, D52, D53, K54 and E186). The side chains of 
K108 appear to extend into the channel pore to constrict the opening. Below this constriction, 
rings of identical, charged amino acids in the M2 domains influence ion selection and 
conduction in the 5-HT3 receptor (Miyazawa et al. (2003) and Hassaine et al. (2014)) . 
Substituting different amino acids in these rings established that single amino acids at either 
end of the M2 domains made the most acute difference in ion selectivity (Thompson and 
Lummis, 2003). 
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The homomeric 5-HT3 receptor is equally permeable to monovalent and divalent cations. The 
incorporation of the 5-HT3B subunit appears to decrease the permeability of the 5-HT3 
receptor to divalent cations such as Ca2+ (Davies et al., 1999). The lack of an acidic residue in 
the outer ring of the M2 domain decreases the conductance of Ca2+ in nACh receptors 
 
1.5.8. Single Channel Conductance 
The conductance of the homomeric 5-HT3 receptor has been measured between 0.40 and 1 pS 
(Brown et al., 1998), which was found to be considerably lower than conductances measured 
in neuronal 5-HT3 receptors. It was found that the heteromeric 5-HT3A/3B receptor displayed a 
conductance of 16 pS (Davies et al., 1999), indicating the 5-HT3B subunit plays a significant 
role in single channel conductance. Five portals are formed of helical amphipathic (HA) 
stretches located in the large intracellular loop between the M3 and M4 domains (Unwin, 
2005). Substitution of the ‘HA’ stretch of the 5-HT3B subunit into the 5-HT3A subunit caused 
an increase in conductance similar to that of the heteromeric 5-HT3A receptor (Kelley et al., 
2003), associating the cytoplasmic region with determining single channel conductance.  
 
1.6. Irritable Bowel Syndrome 
Irritable bowel syndrome affects approximately 5-10% of the global population (Spiller, 
2011). There are no biomarkers of IBS, rather the disease is characterised by recurrent 
symptoms of abdominal pain or discomfort associated with irregular bowel habits, based on 
the Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders (2006). The 
diagnostic criterion for irritable bowel syndrome is recurring abdominal pain or discomfort 
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for at least three days per month in the last three months associated with at least two 
symptoms regarding bowel habits.  
IBS is sub-classed into three categories depending on the predominant bowel symptom: 
diarrhoea-predominant (IBS-D), constipation-predominant (IBS-C) or IBS alternating 
diarrhoea and constipation, termed mixed (IBS-M). Symptoms can manifest between the ages 
of 15 and 65, and are more prevalent in women. Although not lethal, IBS can cause severe 
reduction in quality of life and lead to significant healthcare costs due to symptoms and IBS-
associated diseases, loss of productivity and work absenteeism. In the USA, IBS costs society 
between $1.7 and $10 billion annually (Hulisz, 2004), justifying research into better treatment 
of symptoms. 
 
1.6.1. The Role of the 5-HT3 Receptor in Irritable Bowel Syndrome 
The vast majority (90-95%) of 5-HT in the body is located in the gastrointestinal system and 
it plays an important role in normal gut function. It interacts with the enteric nervous system 
(ENS); a complex network of approximately 100 million neurons. The majority of 5-HT in 
the gut is stored in enterochromaffin cells forming the lining of the GI tract, which function as 
sensory transducers by releasing 5-HT in response to luminal stimuli such as pressure or 
nutrients (Spiller, 2011). A small amount of 5-HT is also found in neurons in the myenteric 
plexus of the ENS. 5-HT activates intrinsic and extrinsic primary afferent neurons to stimulate 
peristalsic and secretory functions, respectively, and relay sensory information to the central 
nervous system (Gershon and Tack, 2007). Figure 4 below illustrates the pathways stimulated 
by 5-HT release in the gut. 5-HT3 receptors have been shown to mediate intestinal secretion 
(Hansen and Skadhauge, 1997), neurogenic smooth muscle contractions in the guinea pig 
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ileum (Buchheit et al., 1985) and increased colonic motility (Talley et al., 1990). These 
symptoms have been blocked by 5-HT3 receptor antagonists such as ondansetron, alosetron 
and ramosetron, reinforcing the notion of 5-HT3 receptor implication in IBS-D (Spiller, 2011). 
 
 
 Figure 4: Illustration of the 5-HT receptors involved in the physiological and pathophysiological 
responses to mucosal stimuli. 5-HT is stored in enterochromaffin cells (in white) and released in 
response to luminal stimuli. 5-HT binds to a variety of nerve endings in the enteric nervous system. 5-
HT1p receptors (poorly characterised receptors found in the ENS) are found on intrinsic primary 
afferent neurons (IPANs), 5-HT3 receptors are located on extrinsic afferent neurons (vagal and 
splanchnic nerves) and on myenteric nerves (not shown) and 5-HT4 receptors are found throughout the 
myenteric plexus.  Signalling is terminated by reuptake via the serotonin transporter (SERT, in blue) 
into the enterchromaffin cells, where 5-HT is metabolised by monoamine oxidase to 5-hydroxyindole 
acetic acid (5-HIAA). (Spiller, 2011) 
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1.6.2. Use of 5-HT3 Receptor Antagonists to Treat IBS-D 
Ondansetron was the first 5-HT3 receptor antagonist to be successfully used to treat the 
symptoms of IBS-D, however, the more potent alosetron was selected for clinical trials as it 
was 3-10 times more potent with longer lasting alleviation of symptoms (Spiller, 2011). A 
meta-analysis of 14 randomised controlled trials (RCT) (Andresen et al., 2008) showed 
administration of alosetron and cilansetron (compared to placebo and mebeverine, an 
antimuscarinic antispasmodic used to treat IBS) significantly alleviated symptoms of IBS and 
were more effective than the comparators. A common side effect of using 5-HT3 receptor 
antagonists was constipation (Andresen et al., 2008), which was cause for approximately 10% 
of patients reporting constipation to discontinue treatment. 
 
1.6.3. Ischaemic Colitis 
Alosetron was approved by the Food and Drug Administration (FDA) in February 2000 and 
marketed by Glaxo Wellcome as Lotronex, but within a few months received 70 reports of 
complications, including 49 of ischaemic colitis and 21 of severe constipation with ruptured 
bowels. Of those 70 cases, 34 were hospitalised, 10 required surgery and 3 deaths were 
reported (Lisi, 2002). As a result of further reports of adverse effects, Glaxo Wellcome 
voluntarily withdrew alosetron in 2000, but reintroduced it in 2002 with a more restricted 
indication and prescribing program to treat only women with severe diarrhoea-predominant 
IBS (FDA, 2012).  
A review of 29 072 patients administered with alosetron under a risk management plan  
showed the incidence of complications around 0.95 cases per 1000 patient years and the 
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symptoms abated when treatment was discontinued (Chang et al., 2010). There were no 
reported surgeries required or any deaths reported, as was previously shown in 2000. 
Ramosetron, another 5-HT3 receptor antagonist is still currently used to treat IBS-D in Japan 
(Matsueda et al., 2008).  
It seems the rationale behind prescribing 5-HT3 antagonists is sound but the restricted access 
for patients limits the beneficial effects. This justifies the need for efficient drugs targeting the 
5-HT3 receptor but without the severe side effects of prolonged antagonism. An interesting 
observation is that 5-HT3 receptor antagonists are widely prescribed to treat chemotherapy-
induced nausea and vomiting post-surgically, yet ischaemic colitis has not been reported as a 
side effect when used in this context. This suggests there could be interactions of 5-HT3 
receptor antagonists specific to patients with IBS.  
 
1.7. Allosteric Modulation  
 
The success of 5-HT3 receptor antagonists such as alosetron to treat the symptoms of IBS-D 
but their failure in their side effect profile emphasises the requirement for a functionally 
similar compound which does not fully block 5-HT3 receptor activity. This is the rationale 
behind allosteric modulators. This would enable a compound to either increase (positive 
allosteric modulator PAM) or decrease (negative allosteric modulator NAM) the activity of a 
receptor in response to the endogenous ligand whilst binding to a different site. These 
compounds have no effect on receptor activity alone, but function by potentiating or reducing 
the response to an agonist or partial agonist.  
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It is hypothesised that a negative allosteric modulator (NAM) would alleviate the 5-HT3 
receptor-mediated symptoms such as nociception, excessive secretion and peristalsis without 
fully abolishing basal levels for normal bowel function.  
 
1.7.1. 5-Chloroindole 
5-Chloroindole (5-Cl) has recently been identified as a potent and selective allosteric 
modulator of the 5-HT3 receptor (Newman et al., 2013). It was shown to potentiate 5-HT3 
receptor agonist and partial agonist responses by increasing the affinity of these agonists for 
the receptor and by reactivating desensitised 5-HT3 receptors both in cell lines expressing the 
recombinant receptor and native tissues (Newman et al., 2013). This study also showed that 
potentiation of agonist-evoked responses did not occur in α7 nicotinic acetylcholine receptors. 
Unpublished data (Grafton G., personal communication) have also found that 5-chloroindole 
had no potentiating effect on 5-HT-evoked responses in a (rat/mouse) chimeric α7V2015-HT3 
receptor (first described in Eiselé et al. (1993)). This chimeric receptor possesses the N-
terminus of the α7 nicotinic acetylcholine receptor, suggesting the binding site for 5-Cl is in 
the N-terminus of the 5-HT3 receptor.  
 
 
Figure 5: Diagram of the chemical structure of 5-chloroindole. Taken from Sigma Aldrich 
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1.8. Aims 
Although it has no likely use clinically due to projected pro-emetic and anxiogenic effects, 5-
chloroindole has proven to be a useful tool for characterising the nature and structure of the 
allosteric binding site. In this present dissertation, I have investigated derivatives of 5-Cl to 
determine a core structure which will bind with high affinity to the allosteric binding site, and 
understand the molecular determinants of negative allosteric modulation. I have also 
attempted to construct a human/human α7V2015-HT3 chimeric receptor to confirm findings in 
the equivalent rat/mouse chimera, and locate the allosteric binding site to the N-terminus of 
the 5-HT3 receptor. Expanding our knowledge of the structure-activity relationship of the 
allosteric binding site will allow a more rational drug design of negative allosteric modulators 
with potential therapeutic benefits.  
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CHAPTER 2 : MATERIALS AND METHODS 
2.1. Use of Mammalian Cell Lines 
2.1.1. Maintenance of HEK-293 Cells 
Stable cell lines expressing recombinant human 5-HT3A receptors were cultured in complete 
medium containing Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma, D5796) 
supplemented with 10% (v/v) foetal bovine serum (FBS, Sigma F2442) and a 100 µg/mL 
penicillin/streptomycin antibiotic solution (Invitrogen, 15140122). The cells were grown in 
75cm2 (T75) sterile tissue culture flasks in a LEEC cell culture incubator which maintains 
100% relative humidity, the temperature at 37°C and the CO2 levels at 5%. Sterile conditions 
were maintained by using a class II microbiological safety cabinet (air filtration system), 
using filter sterilised solutions (Millipore 0.22 µM filters), sterile serological pipettes and 
autoclaved utensils.  
Cells were regularly passaged to maintain healthy proliferation and provide room for growth. 
Around 100% confluence, the medium was aspirated off the cells, which were then washed 
with Ca2+- and Mg2+-free phosphate buffer saline (PBS, Invitrogen, 14200067) and incubated 
for 5 minutes at 37°C in a 1 mL trypsin/EDTA solution (2.5 g/L and 0.2 g/L respectively, 
Sigma, T4174). Once trypsinised, complete medium was added to the cells to inhibit the 
trypsin. Routinely, 9 mL medium was added to the flask, to makeup a final volume of 10 mL. 
To perform a 1:5 passage, 2 mL were taken from this 10 mL cell suspension and transferred 
to a new flask, and the final volume made up to 15 mL with medium. The factor of dilution 
refers to the volume of cells taken from the diluted trypsin cell suspension, and manipulating 
this dilution factor controls the speed of growth and proliferation. Human embryonic kidney 
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293 (HEK293) cells transfected with DNA encoding the 5-HT3A receptor required weekly 
innoculations with 0.5 mg/mL geneticin (G418). The number of passages was recorded by 
adding 1 to each generation number and cells were considered viable up to passage 45.  
 
2.1.2. Preparation of Whole Cell Lysates 
Protein samples for experiments were obtained from cell lines expressing the protein of 
interest. Once the medium was removed and the cells washed with 5 mL PBS, the cells were 
removed using a cell scraper, which physically scrapes the cells off the bottom of the flask. 
The cells were then resuspended in 10 mL PBS and transferred to a 50 mL centrifuge tube, 
and centrifuged at 400 x g for 5 minutes. The supernatant PBS was aspirated  and discarded to 
leave a cell pellet at the bottom of the tube. Cell pellets being used for downstream 
experiments were resuspended in 1 mL 50 mM Tris pH7.4 and kept on ice. Those not being 
used immediately were stored dry at -80°C for later use. 
To obtain whole cell lysates, the cells were homogenised to release intracellular proteins and 
liberate cell surface proteins. Cells were lysed using a sonicator, a vibrating probe which 
vibrates at a high frequency to disrupt cell membranes. The samples were sonicated on ice in 
5 pulses of approximately 5 seconds each, so as not to overheat the protein. 
 
2.1.3. Bradford Protein Quantitation 
The Bradford protein assay is a colourimetric protein assay. The colour change is caused by 
binding of protein to Coomassie Brilliant Blue G-250. The increase of absorbance at 595 nm 
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is proportional to the amount of bound dye, and thus to the amount (concentration) of protein 
present in the sample. The Bradford assay is linear at a range of 100 to 1400 µg/mL (for the 
reagent used).  
The spectrophotometer was calibrated using bovine serum albumin, the most widely 
recognised protein standard for Bradford protein assays. 20 µL of concentrations of bovine 
serum albumin (BSA) ranging from 0.2 to 1 mg/mL were added to 1 mL Bradford reagent 
(Sigma, B6916). 
The spectrophotomer was initially blanked with 1 mL Bradford reagent and 20 µL of 50 mM 
Tris pH 7.4, then 20 µL of the samples were incubated in 1 mL Bradford reagent at room 
temperature for at least 5 minutes to allow the colour to develop. The spectrophotometer 
would display both the absorbance of the sample and the sample protein concentration, 
obtained from calibration. The whole cell homogenates could then be diluted in 50 mM Tris 
pH 7.4 to the desired concentration for further experimentation. 
 
2.2. Assessment of [Ca2+]i  
FlexStation analyses measure the amounts of free cytoplasmic calcium in HEK293 cells 
expressing human 5-HT3A receptors. The calcium-binding dye Fluo-4 AM (acetoxymethyl) is 
a lipid-soluble ester which permeates the cell membrane. Once inside the cell, the host cell 
esterases cleave the AM compound, rendering fluo-4 trapped inside the cell, thus enabling the 
intracellular calcium to be labelled. Activation of the 5-HT3A receptor will thus trigger the 
influx of Ca2+ ions, causing an increase in fluorescence once the dye has bound to calcium. 
One pitfall of this method is that the limiting factor is the amount of fluo-4 inside the cell, 
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signifying the response is saturatable. Other calcium binding dyes were also tested, but 
showed no difference in saturation levels (data not shown). 
Black-walled, clear bottom, 96-well plates (Corning, CLS3603) were treated with sterile, 
warm, poly-D-lysine (Sigma, P6407) for 30 minutes in a biological safety hood. The poly-D-
lysine was then removed and the remnants were rinsed off with filter sterilised water. Once 
dry, the plates were ready to be used for tissue culture.  
HEK293 cells expressing human 5-HT3A receptors were plated at approximately 1 x 105 cells 
per well and incubated overnight in DMEM in a tissue culture incubator. In preparation for 
FlexStation analysis, the cells were rinsed twice in Hank’s balanced salt solution (HBSS) 
buffer (Gibco, 14025092) and then incubated with 5 µM Fluo-4 AM (Invitrogen, F-14201) for 
one hour at room temperature. The cells were then washed twice in HBSS and then incubated 
in HBSS for a further 30 minutes to remove any extracellular fluo-4.  
Drug plates (96-well clear-walled, clear bottom, Corning, 2503) were prepared with ranging 
concentrations of the drugs of interest. The drugs plate and cell plate were loaded into and run 
by a FlexStation benchtop scanning fluometer (Molecular Devices), which reads the column 
of 8 wells simultaneously, over a time course, during which up to three compounds can be 
added. Alterations of intracellular calcium concentrations in response to various 
concentrations of 5-HT (10-5 to 10-8) in the absence and presence of various compounds were 
measured.  
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2.3. Radioligand binding 
Competition radioligand binding studies the ability (or lack of) of a ‘cold’ unlabelled 
compound to compete at different concentrations for a specific target with one concentration 
of a radiolabelled compound (‘radioligand’). The amount of radioligand still bound to the 
target can then be measured by liquid scintillation counting, and a binding curve produced. 
All data are produced in triplicates. 
Ice cold 50 mM Tris buffer (Trizma base, Sigma), pH 7.4, was used throughout the 
experiment for dilution of drugs, cell membrane preparations and the washing stage during 
harvesting. ‘Cold’ competing drugs were weighed and diluted in buffer or initially to stock 
concentrations of 10 mM, then diluted to concentrations spanning their IC50s, the 
concentration of drug producing 50% of a response. Allosteric modulators were diluted in 
dimethyl sulphoxide (DMSO, Sigma, D8418), due to their insolubility in water.  
 
Drug Manufacturer, Product number Molecular Weight (g/mol) Dissolved in 
Radioligand 
[3H]-granisetron: 
BRL-43694, [9-methyl-
3H] 
Perkin Elmer, 
NET1030250UC 1 µCi/µL in 100% ethanol 50 mM Tris 
Cold Competing Drug 
5-HT Sigma, H9523 292.93 50 mM Tris 
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Ondansetron Tocris Bioscience, 2891 329.83 50 mM Tris 
Quipazine Sigma, Q1004 329.40 50 mM Tris 
(S)-zacopride 
Department of 
Chemistry, University 
of Birmingham 
345.20 50 mM Tris 
Allosteric Modulators 
5-Chloroindole Sigma, C47604 151.59 DMSO 
5-(trifluoromethyl)-
indole Sigma, 701068 185.15 DMSO 
5-bromoindazole 
Department of 
Chemistry, University 
of Birmingham 
151.70 DMSO 
5-bromo-
benzimidazole 
Department of 
Chemistry, University 
of Birmingham 
151.50 DMSO 
 
The buffer, allosteric modulators, ‘cold’ drug, radioligand and membrane preparations were 
added in triplicates to binding tubes to a final volume of 500 µL as shown in table 1. 
Concentrations of the ‘cold’ drugs were prepared 3 x concentrated and the radioligand was 
prepared 5 x concentrated so as to reach the correct final concentration in the total reaction 
volume. The samples were incubated at room temperature for one hour before termination by 
rapid filtration. During this incubation time, glass fibre filters (Whatman GF/B, Brandel) were 
soaked in a 0.3% polyethyleneimine solution (PEI, Sigma, P3143).  
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 Buffer (µL) ‘Cold’ drug (µL) Radioligand (µL) Membranes (µL) 
Control 150 0 100 200 
Experimental 
conditions 0 150 100 200 
Table 1: Volumes of reagents added to binding tubes. Control tubes are to show total binding. 
Experimental conditions describe the range of concentrations of competing drug added. 
 
A 48 sample Brandel cell harvester was used to terminate the reactions by separating unbound 
ligand from ligand-bound receptor through the glass fibre filters. The system, joined to a 
vacuum pump aspirates the samples in the tubes, whilst washing with ice-cold 50 mM Tris pH 
7.4. Samples were washed 3 times for 4 seconds each.  
Once samples were harvested, the filtration unit was opened, the filters were cut and placed 
into polypropylene scintillation vials, and soaked overnight in 4 mL of scintillation cocktail 
(Scintisafe 3, Fisher). The next day the scintillation vials were placed in a Packard 1500TR 
Liquid Scintillation Analyser to measure the amount of radioligand-bound receptor on the 
filters in disintegrations per minute (DPM).  
 
2.4. Data Interpretation 
In intracellular calcium (FlexStation) studies, data (relative fluorescent units RFU) were 
analysed in SoftMax Pro 4.8 and RFU was plotted as a percentage of the maximal 5-HT 
response in Kaleidagraph 3.5 (Synergy). 
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In radioligand binding studies, data were plotted as DPM against the concentration of 
competing drug in KaleidaGraph 3.5, (Synergy), and a four parameter logistical equation was 
used to obtain the IC50 and Hill number for each curve. 
Below is the logistical equation used: 
m4-(m1*((m0^m3)/((m0^m3)+(m2^m3)))) 
Where:  m1 is the specific binding (total – non-specific binding) 
m2 is the IC50 of the drug 
m3 is the Hill coefficient 
m4 is the total binding 
The total binding (m4) and specific binding (m1) were corrected by inserting values obtained 
from initial curve fits.  
The Ki of the drug was calculated using the Cheng-Prussoff equation:  
 
Ki = IC50
(1+RLKd )
 
Where : IC50 of the ‘cold’drug 
[RL]: concentration of radioligand 
Kd: dissociation constant of the radioligand 
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2.5. Statistical Analysis 
Data obtained from graphical analysis were analysed using GraphPad Prism 5.0. The Kd 
(dissociation constants) and Hill coefficients obtained from radioligand binding competition 
studies were initially tested for normality using the Shapiro-Wilk normality test. As the data 
were found to not be normally distributed, the Mann-Whitney U test was adopted.  
Analysis of variance (ANOVA) was used to compare data points and test for a significant 
difference between any data points on graphs. Significance was reached if p < 0.05. 
 
2.6. Methods in DNA Preparation 
2.6.1. Plasmid Vectors 
2.6.1.1. α7 Nicotinic Acetylcholine Receptor 
The human α7 nicotinic acetylcholine receptor nucleotide sequence (GenBank accession no. 
NM_000746.5) was inserted into pCI-neo (Promega, E1841), a 5.5kb plasmid with a 
cytomegalovirus (CMV) enhancer/promoter region; with NotI/XhoI ends. It contains a 
bacterial resistance gene for ampicillin, and a neomycin phosphotransferase gene, which acts 
as a selectable marker for mammalian cells. Below is the map of pCI-neo with the insert, 
constructed in Serial Cloner v 2.6.1.  
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Figure 6: Plasmid map of the pCI-neo vector with human α7 nicotinic acetylcholine receptor 
insert. Reference points and positions in the plasmid are indicated in the map (obtained from 
Promega) : F1 ori : F1 origin, Kan/neoR : kanamycin /neomycin resistance gene, AmpR : 
ampicillin resistance gene. 
 
2.6.1.2. 5-HT3A Receptor 
The human 5-HT3A receptor nucleotide sequence (GenBank accession no. NM_000869.5) 
was inserted into pcDNA3.1/myc-His (Invitrogen, V800-20), a 5.5kb plasmid, also expressing 
a CMV enhancer/promoter region; with BamHI/XbaI ends. It contains a bacterial ampicillin 
resistance gene, and a neomycin phosphotransferase gene for transfected cell selection. Below 
is the map of the pcDNA3.1 with the human 5-HT3A insert. 
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Figure 7: Plasmid map of pcDNA3.1/myc-His with human 5-HT3A insert. Reference 
points and positions in the plasmid are indicated in the map (obtained from Invitrogen). T7 : 
T7 promoter, h5-HT3A : human 5-HT3A insert, 6His : his tag, BGH rev : BGH reverse 
plasmid primer, bGH PA : bGH PA terminator, F1 ori : F1 origin, SV40 ori : SV40 origin, 
Kan/neoR : Kanamycin / neomycin resistance gene, AmpR : ampicillin resistance. 
 
2.6.2. DNA Sequencing 
Native and recombinant plasmid DNA was sequenced by dye-termination sequencing, derived 
from Sanger’s chain-termination method (Sanger and Coulson, 1975), by the Functional 
Genomics Facility (University of Birmingham). Sequences were imported and 
chromatograms visualised using Chromas Lite v2.1.1. Chromatograms appear as the DNA 
sequence with peaks of colour representing each nucleotide (thymine in red, adenine in green, 
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guanine in black and cytosine in blue). The height of a peak represents the degree of 
fluorescence for a nucleotide in that position; hence the higher the peak, the higher the 
fluorescence. Additionally, above each peak is a coloured bar, representing the order of 
magnitude of the probability of error for that base. A full bar indicated a probability of less 
than 1:1 000 000 that the base is incorrect. The quality of the chromatogram can thus be 
determined by these indicators, and viable sequences were selected on this basis. The 
sequence files were then exported to a FASTA format to analyse the data. The FASTA files 
were copied into BLAST and aligned with the consensus sequences for each receptor (See 
sections 2.6.1.1. and 2.6.1.2.) 
 
2.6.3. DNA Quantitation 
DNA obtained from PCR or gel extractions was purified and resuspended in nuclease-free 
water. The DNA concentration in solution was measured using a microvolume 
spectrophotometer (Nanodrop 2000TM, Thermo Scientific).  
The Nanodrop was initially blanked by pipetting 2 µL of the nuclease-free water in which the 
DNA was resuspended. DNA was measured (in ng/µL) by adding 2 µL of the DNA sample to 
the Nanodrop. DNA is measured at 260 nm, the wavelength at which it absorbs light (Dahm, 
2008)., the sample is exposed at 280nm to measure for sample purity and the ratio of 
absorbances at 260 and 280nm (260/280) is calculated. A ratio of 1.8 is generally accepted as 
pure for DNA. If the ration is lower, this could indicate the presence of proteins or other 
contaminants that absorb strongly at 280nm. A secondary measure of sample purity is the 
260/230 ratio. Pure sample ratio values are expected around 2-2.2.  
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2.6.4. Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used to separate DNA fragments by size. A 1% agarose gel 
was made with 2 g agarose in 200 mL 1 X TAE buffer (see table 3) and heated to dissolve the 
agarose powder. Once cooled, 20 µL Sybr®Safe was mixed into the gel, which was then was 
cast in a casting tray with sealed edges and a comb, and left to set. The gel was placed in an 
electrophoresis tank (Thistle Scientific) and submerged in 1 X TAE buffer.  
 
 
 
 
 
 
 
Table 2: Composition of 50 X TAE Electrophoresis Buffer 
 
 
 
50X TAE Buffer – 1L  
Trizma Base (Sigma T1503) 242g 
Glacial Acetic Acid (Fisher  
10304980) 
57.1mL 
EDTA (0.5M) 100mL 
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Table 3: Composition of 1% Agarose Gel 
 
To allow identification of samples, 5 µL HyperLadder™ I (Bioline, BIO-33053) was loaded 
directly into one well. 5 X DNA loading buffer (Bioline, BIO-37045) was added to DNA 
samples to a final 1 X concentration, then samples were loaded into wells in the gel. The gel 
was typically run at 100 V for between 1 and 1.5 hours, depending on fragment size.  
Once the gel had run, it was removed from the electrophoresis tank and placed in a gel 
visualiser (Syngene) coupled to a computer to adjust lighting settings and take screen shots of 
the gel. The bands obtained could be compared to the DNA ladder to determine their size. The 
gel could then be placed on a blue light transilluminator (Invitrogen), and the desired bands 
were cut out using a scalpel blade for downstream molecular biology.  
 
2.6.5. Gel Extraction and Purification 
DNA bands of interest were excised from the agarose gel and the DNA extracted from the gel 
using a commercially available kit (GenElute Gel Extraction Kit, Sigma, NA1111), following 
the manufacturer’s specifications. The kit combines silica binding technology with a spin 
1% Agarose Gel 
1X TAE buffer 200 mL 
Agarose (Sigma A9539) 2 g 
Sybr®Safe DNA Gel Stain 
(Invitrogen S3312) 
20 µL 
39 
 
column format to separate the DNA from the agarose gel. The gel slices were weighed, then 
three gel volumes of gel solubilisation solution added (i.e. for 100 mg of gel, 300 µL of gel 
solubilisation solution was added). The gel slices were incubated in a water bath at 60°C for 
10 minutes, allowing the gel to melt. One gel volume of 100% isopropanol was added to 
precipitate the DNA. The solution was then loaded into columns containing a silica membrane 
and spun in a microcentrifuge at 12 000 x g for 1 minute, and the flowthrough was discarded. 
The column was then washed with wash solution containing 100% ethanol, to wash salts and 
impurities out of the matrix. The DNA was finally eluted out of the silica membrane and 
collected in a microcentrifuge tube by using 50 µL of low ionic elution buffer.  
To resuspend the DNA in nuclease-free water and remove impurities caused by the extraction 
process, the DNA was purified using the purification steps described in step 2.6.6. 
 
2.6.6. DNA Purification 
 DNA samples were incubated at -20°C for 20 minutes with 0.1 volumes of 3 M sodium 
acetate pH 5.2 (Sigma, 71196) and 2.5 volumes of ice cold 100% ethanol, to precipitate the 
DNA. They were then spun in the microcentrifuge at 14 000 x g for 30 minutes to pellet the 
DNA. The supernatant was removed, and then samples were spun again for 1 minute in 1 mL 
70% ice cold ethanol. Two washes in 1 mL 100% ice-cold isopropanol were then performed 
in the microcentrifuge at 14 000 x g for 1 minute each. The samples were then left to air dry, 
and resuspended in 100-500 µL nuclease-free water.  
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2.6.7. Construction of a Chimeric α7V2015-HT3A Receptor 
  
2.6.7.1. Overlap Extension Polymerase Chain Reaction 
Overlap extension PCR is a form of PCR allowing two fragments of DNA to be amplified and 
joined together. This method was used with the aim of constructing the chimeric α7V2015HT3A 
receptor.  
Primers in table 4 were designed using the online nucleotide and protein sequence storing tool 
Biology Workbench (San Diego Supercomputer Center), then synthesised by Alta Bioscience 
Ltd (University of Birmingham) and Sigma. The primers were resuspended in nuclease-free 
water to a stock concentration of 100 µM, according to the manufacturer’s specifications; then 
diluted in nuclease-free water to the correct concentrations for downstream use. 
The forward flanking (FF) primer sequence was complementary to the 5’ end of the α7 
nicotinic acetylcholine receptor N-terminus, and the reverse chimeric primer (RC) was 
complementary to the 3’ end of the N-terminus sequence (in blue), and the 5’end of the 5-
HT3A receptor (in red). These two primers were used to amplify the α7nACh N-terminus 
sequence. The reverse flanking primer (RF) was complementary to the 3’ end of the 5-HT3A 
receptor sequence, and the forward chimeric primer (FC) was complementary to the 3’ end of 
the α7nACh N-terminus sequence and the 5’ end of the 5-HT3A template. These two primers 
were used to amplify the 5-HT3A sequence.  
 
 
41 
 
 
Table 4: Primer name and sequence used for overlap extension PCR. Blue sequences represent α7 
nAChR sequences. Red sequences represent 5-HT3A sequences. Green sequences show restriction sites 
BamHI in the α7 FF primer, XbaI in the 3A RF primer and MreI in the CRev1 primer. 
In the first step of overlap extension PCR, a 50 µL PCR preparation consisted of: 5µL of 10X 
Pfu Polymerase buffer with MgSO4 (Promega, M776A), 100 ng of each DNA template, 25-50 
µmoles of one flanking primer and one chimeric primer, 200 µmoles of each deoxynucleotide 
triphosphate (dNTPs, Promega U1515), 1.5-3 units Pfu Polymerase (Promega M774A) and 
the final volume completed to 50 µL with nuclease-free water.  
The PCR was conducted in the conditions as described in tables 5 and 6. The products 
obtained were one α7nACh receptor N-terminus sequence with a 3’ overhang belonging to the 
5-HT3A receptor sequence, and one 5-HT3A fragment with a 5’ overhang belonging to the 
α7nACh receptor sequence. The 5-HT3A overhang on the α7nACh receptor fragment is 
Primer Name Primer Sequence 
α7 Forward Flanker FF (Alta Bioscience) 5’-TCACTATAGGGATCCCTCGAGGCCACCATGCGCT-3’ 
α7/3A Reverse Chimeric RC (Sigma) 5’-CCGCCGGCGGATGACCACTGTGAAGGTGACAT-3’ 
α7/3A Forward Chimeric FC (Sigma) 5’-ATGTCACCTTCACAGTGGTCATCCGCCGGCGG-3’ 
3A Reverse Flanker RF (Alta Bioscience) 5’-GTTCGAAGGGCCCTCTAGATGCATGCTCGAGGTCG-3’ 
Chimeric Reverse Primer CRev1 (Sigma) 5’- GGCCGCCGGCGGATGACCACTGT – 3’ 
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complementary to the 5’end of the 5-HT3A fragment, and the α7nACh overhang on the 5-
HT3A fragment is complementary to the 3’ end of the α7nACh fragment. The PCR products 
were separated by agarose gel electrophoresis to identify the correct bands (see section 2.6.4). 
The bands of the correct size (721 bp for the α7nAChR fragment and 1.1 kb for the 5-HT3A 
fragment) were extracted and purified from the gel. The PCR products obtained possessed 
complementary overhangs, therefore were introduced in a second round of PCR with only the 
FF and RF primers to produce the full chimeric sequence.  
 
 
Figure 8: Graphical representation of overlap extension PCR of the human nicotinic acetylcholine 
receptor (h-α7nAChR, blue) sequence and human 5-HT3A receptor (h5-HT3A, red) sequence to form a 
chimeric human/human α7V2015-HT3 receptor sequence. Arrows represent complementary primers. 
FF: forward flanking primer, RF: reverse flanking primer, FC: forward chimeric primer, RC: reverse 
chimeric primer.  
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Table 5: PCR reaction components 
  
 
 
 
 
 
PCR reaction 
10 X Pfu Buffer 
Promega M776A 
5 µL 
DNA Template 100 ng 
Complementary primers 25-50 µmoles 
dNTPs  
Promega U1515 
200 µmoles each 
Pfu polymerase (units U)  
Promega  M774A 
1.5-3 U 
ddH2O Make up to 50 µL 
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Table 6: Temperature and cycle conditions for PCR 
 
Many variations of primer sequences and cycling parameters were tested to optimise PCR 
conditions, but due to the short overhangs produced by the first round of PCR, these were not 
sufficient to prime the next round of PCR and produce the chimeric receptor sequence. A 
different method was devised by identifying a restriction site specific to the overhang region 
and absent in the coding sequence for both α7nAChR and 5-HT3A. This would then allow 
digestion of the overlap region, producing complementary ends on each sequence, to then 
ligate the two fragments together.   
 
 
 
Step Temperature (°C) Time (minutes) Cycles 
Initial denature 95 2 1 
Denature 95 1 
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Annealing 65-75 1 
Extension 72 2-5 
Final Extension 72 5 1 
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2.6.7.2. Restriction endonuclease digest 
Restriction endonucleases are enzymes typically found in bacteria to digest foreign DNA as a 
defence mechanism, and have been identified as critical tools in many applications such as 
cellular analysis, protein expression and purification, epigenetics, DNA modification and 
cloning. These enzymes recognise specific palindromic sequences of 4 to 8 nucleotides, 
termed restriction sites and cleave the DNA at these sites. The enzymes can produce ‘blunt’ 
ends, where the double-stranded DNA is cut in the same place on both strands; or they can 
produce ‘sticky’ ends, where the strands are cut in different places, creating an overhang. 
Different DNA fragments which are cut with the same restriction enzyme have 
complementary ends and can be joined together.  
An MreI restriction site was identified specifically in the 5-HT3A receptor sequence at the 
overlap region for constructing the chimera. As the restriction site was present in the 5-HT3A 
receptor sequence, the 5-HT3A fragment could be cleaved directly out of its plasmid vector. 
The α7nAChR did not contain the MreI site, therefore the site was introduced by PCR by 
using the α7 FF primer (see table 4) and a chimeric reverse primer (CRev1, see table 4) 
containing the 5-HT3A overhang and the MreI site. The α7 fragment would then contain the 
restriction sites BamHI at the 5’ end and MreI at the 3’ end. Table 7 shows the cleavage sites 
for the enzymes used during experiments.  
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Endonuclease Sequence Cleaved 
Fastdigest MreI (Thermo Scientific, FD2024) 
5’-CG/CCGGCG-3’ 
3’-GCGGCC/GC-5’ 
Fastdigest BamHI (Thermo Scientific, FD0054) 
5’-GG/ATCC- 3’ 
3’-CCTAG/G-5’ 
Fastdigest XbaI (Thermo Scientific, FD0684) 
5’-T/CTAGA-3’ 
3’-AGATC/T- 5’ 
Table 7: Enzyme restriction site recognition 
 
The Fastdigest enzymes are restriction enzymes artificially altered to cleave 1µg of DNA in 5 
minutes. The MreI restriction site was found to cleave the entire chimeric sequence once at 
the crossover point between α7 nicotinic acetylcholine sequence and 5-HT3A sequence. This 
enzyme was used to cleave the PCR products obtained from overlap extension PCR to then 
ligate the two fragments together and form the full length chimeric sequence.  
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Table 8 : Components for a digest of the α7nAChR PCR product 
 
 
pcDNA3.1-5HT3A Digest 
10X Fastdigest buffer  5 µL 
DNA 5 µg 
MreI (Thermo Scientific, 
FD2024) 
5 µL 
XbaI (Thermo Scientific, 
FD0684) 
5 µL 
ddH2O Final volume of 50 µL 
Table 9: Components for a digestion of pcDNA3.1-5HT3A 
 
 
α7nAChR PCR Product Digest: Fragment 1 
10X Fastdigest buffer  5 µL 
DNA Up to 200 ng 
BamHI (Thermo Scientific, FD0684) 1 µL 
MreI (Thermo Scientific, FD2024) 1 µL 
ddH2O Final volume of 50 µL 
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The digest reactions were incubated at 37°C for 10 minutes, followed by heat inactivation at 
80°C for 5 minutes. Digested fragments were then separated by agarose gel electrophoresis to 
remove the small digested fragments, to prevent re-ligation in further experiments.  
 
2.6.7.3. DNA Ligation 
DNA ligation is the process of joining nucleotides together using a catalyst. T4 DNA ligase, 
obtained from bacteriophage T4, catalyses the formation of phosphodiester bonds between 
nucleotides, thus joining fragments together. The plasmid vector pcDNA3.1, and the chimeric 
nucleic acid sequence previously underwent a double digest with XbaI and BamHI, creating 
cohesive ends. The plasmid vector pcDNA3.1 (Invitrogen) and the chimeric α7V2015HT3A 
receptor sequence were added at different molar ratios (vector : insert) to optimise the ligation 
of the chimera into the vector, and incubated with 0.3 units of T4 DNA ligase (Promega, 
M1801). The reaction was incubated at 4°C overnight. The ligation reaction components are 
described in the table below, and the expected size of the plasmid with the chimeric insert was 
7.3 kb. 
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Ligation Reaction 
Vector DNA 100 ng 
Insert DNA 17 ng 
T4 Ligase 10X Buffer 1 µL 
T4 DNA Ligase (Weiss units) 0.3 units 
Total Reaction Volume made up with dH2O 10 µL 
Table 10: Components for a ligation reaction 
 
To ensure successful ligation, some of the product was digested with the same restriction 
enzymes used to digest the chimeric insert (see section 2.6.7.2.), the undigested and digested 
product were run in a 1% agarose gel, against Hyperladder I™ (Bioline). The band marking 
the successfully ligated insert in the plasmid was apparent between the 6 and 8 kb marker in 
Hyperladder I™; the undigested product as a smeary band, due to the supercoiled nature of 
the plasmid, and the digested plasmid as a clear band with no smears, as the restriction 
enzymes had linearised the product.  
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2.6.8. Use of Bacterial Hosts 
2.6.8.1. Bacterial Culture 
All preparations and handling bacterial cultures were carried out in a sterile environment 
under a Bunsen burner. Culture medium was autoclaved to preserve sterility. Liquid bacteria 
cultures were grown at 37˚C, in an elliptical incubator (New Brunswick, Innova 4400), 
shaking at 225-250 rpm, in 25 g/L Luria-Bertani (LB) medium (Sigma, L3397), supplemented 
with 100 µg/mL ampicillin (Invitrogen, 11593027). Solid phase bacterial cultures were grown 
on 2% (w/v) agar (Sigma, A5306), dissolved and autoclaved in LB medium, then 
supplemented with 100 µg/mL ampicillin once cooled and set in sterile agar plates.   
 
Luria Bertani 
Medium 
Tryptone 10 g/L 
Yeast Extract 5 g/L 
NaCl 5 g/L 
Table 11: Composition of Luria-Bertani Medium 
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2.6.8.2. Bacterial Transformation 
Bacterial transformation is a naturally occurring process which allows bacteria to exchange 
DNA, adapt and evolve, in situations such as damaged DNA. Bacteria which can accept 
foreign DNA are termed competent. Supercompetent XL10 Gold® E. coli (Agilent, 200314) 
were used to grow large quantities of DNA for further molecular biology.  
To transform the bacteria, 200 µL supercompetent XL10 Gold E. coli (Agilent, 200314) were 
incubated with approximately 50 ng of the recombinant DNA on ice for 20 minutes. They 
were then heat shocked for 45 seconds in a water bath at 42˚C and then placed on ice for a 
further 3 minutes. The bacteria were then incubated in 500 µL LB broth at 37˚C, in the 
elliptical incubator for 1.5 hours. Each bacterial transformation was spread on an agar plate, 
left to dry, and incubated overnight at 37˚C.  
 
2.6.8.3. DNA Extraction and Purification from Bacterial Cells 
Large scale extraction and purification of DNA from bacteria generates a high yield of DNA, 
which is useful for mammalian cell transfections. Transformed bacteria are grown in large 
volumes in overnight bacterial cultures, to then undergo alkaline lysis with sodium dodecyl 
sulphate (SDS), a method developed by Birnboim and Doly (1979). Commercially available 
kits (Qiagen Plasmid Maxi Kit, 12163) rely on this basis to purify plasmid DNA from 
bacterial cells.  
Single colonies without microsatellites were selected from the agar plates and inoculated in 5 
mL LB medium supplemented with ampicillin and incubated at 37˚C for approximately 8 
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hours. The cultures were then tipped into Erlenmeyer flasks containing 300 mL LB broth and 
100 µg/mL ampicillin. The flasks were incubated in the elliptical incubator at 37˚C overnight.  
The following day, the bacterial cultures had exponentially grown and filled the flasks. The 
contents of the flasks were divided into 50 mL centrifuge tubes and the cells harvested at 
4000 x g for 10 minutes. The supernatant medium was then discarded, then the cells were 
resuspended in 10 mL resuspension buffer containing RNase A (see table number 12) until no 
cell clumps remained. The cells were then lysed with 10 mL lysis buffer, mixed by inverting 
the tubes and incubated at room temperature for 5 minutes. The Qiagen® Plasmid Maxi Kit 
contains LyseBlue, a colour indicator which turns the cell suspension blue when the lysis 
buffer has been homogenously mixed. 10 mL chilled precipitation buffer was added to the 
lysate, mixed until the suspension became colourless, then incubated on ice for 20 minutes. 
The lysate was then transferred to Beckman Coulter polycarbonate centrifuge tubes (Beckman 
Coulter, 41121703), and centrifuged at 18 000 x g for 30 minutes at 4°C in an ultracentrifuge 
(Beckman Coulter) to remove the precipitated genomic DNA, proteins and cell debris in SDS. 
The clear supernatant solution was isolated, and then centrifuged again at 18 000 x g for 15 
minutes at 4°C. The clear supernatant was loaded onto a pre-equilibrated maxiprep column, 
and allowed to enter the resin matrix by gravity flow. The column was then washed with 30 
mL wash buffer to remove most contaminants, and then washed a second time to remove 
carbohydrates.  
The DNA bound to the resin was eluted in 15 mL elution buffer, and precipitated by adding 
10.5 mL (0.7 volumes) of room temperature isopropanol. The preparation was mixed and 
centrifuged at ≥ 15 000 x g for 30 minutes at 4°C. The supernatant was discarded, the DNA 
pellet was washed with 5 mL of room temperature ethanol and centrifuged at ≥ 15 000 x g for 
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10 minutes at 4°C. After removing the supernatant and air-drying the pellet, it was 
resuspended in 100-500 µL nuclease-free water. The purified DNA could then be quantified 
by microvolume spectroscopy as described in section2.6.3., and then used for downstream 
molecular biology. 
 
Buffer Composition 
Resuspension Buffer P1 
50 mM Tris-HCl, pH 8.0 
10 mM EDTA 
100 µg/mL RNase A 
Lysis Buffer P2 
200 mM NaOH 
1% (w/v) SDS 
0.1% (v/v) LyseBlue 
Precipitation Buffer P3 3.0 M Potassium acetate, pH 5.5 
Wash Buffer QC 
50 mM MOPS, pH 7.0 
15% (v/v) Isopropanol 
1.0M NaCl 
Elution Buffer QF 
50 mM Tris-HCl, pH 8.5 
1.25 M NaCl 
15% (v/v) Isopropanol 
Table 12: Composition of the Qiagen® Plasmid Maxi Kit Buffers 
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CHAPTER 3: RESULTS 
3.1. 5-Chloroindole Potentiates Full and Partial Agonist Responses 
 
 
Figure 9: Ability of 10 and 30 µM 5-chloroindole to potentiate the intracellular Ca2+ concentration in 
response to 5-HT in HEK293 cells stably expressing the human 5-HT3A receptor, shown in relative 
fluorescence units. These data are representative of three independent experiments. 
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Figure 10: Concentration-response curve from intracellular calcium in HEK293 cells stably 
expressing the human 5-HT3A receptor. Error bars are mean ± standard error of the mean (SEM) of 3 
independent experiments. 
 
Results from intracellular calcium studies, as shown by the representative response curve in 
figure 9, showed that the concentration of intracellular calcium (shown in relative 
fluorescence units, RFU) reached a maximum fluorescence at approximately 30000 RFU. 5-
Cl increased the maximal level of fluorescence, as well as decreasing the concentration of 5-
HT required to elicit an equal level of fluorescence. Figure 10 shows the responses relative to 
maximal 5-HT responses. The maximal 5-HT response was increased by approximately 30% 
in the presence of 5-Cl and a leftward shift in the dose response could also be seen in the 
presence of 30 µM 5-Cl, showing a decrease in the EC50 of 5-HT in the presence of 5-Cl.  
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To study allosteric properties of 5-Cl, [3H]-granisteron competition binding studies were 
performed to explore the effects of 5-Cl on full and partial agonist activity at the human 5-
HT3A receptor.  
 
 
Figure 11: Competition of 5-HT for [3H]-granisetron in the absence and presence of 10 µM 5-Cl in 
the human 5-HT3A receptor. Error bars represent mean ± SEM. n=3 
 
 
 pKi ± SEM Hill number ± SEM 
5-HT 5.67  ± 0.18 2.44  ± 0.14 
5-HT + 10 µM 5-Cl 6.38  ± 0.22 1.65 ± 0.19 
Table 13: pKi and hill numbers extrapolated from curve fit equations from graphs such as in 
figure 11. Data are mean ± SEM. N=3.  
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Figure 11 shows the competition of 5-HT with [3H]-granisteron for the 5-HT3A receptor. 
There was no difference in maximum binding in the absence and presence of 10 µM 5-Cl. 10 
µM 5-Cl did however cause the leftward shift in the dose response, suggesting an increase in 
the binding affinity of the receptor for 5-HT. This increase in affinity was however not 
significant, as shown in table 13. There was also no difference between hill numbers.  
 
 
 
Figure 12: Competition of quipazine for [3H]-granisetron in the absence and presence of 10 µM 5-Cl 
in the h5-HT3A receptor. Error bars represent mean ± SEM. n=4 
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 pKi ± SEM Hill number ± SEM 
Quipazine 8.13  ± 0.06 1.44 ± 0.24 
Quipazine + 10 µM 5-Cl 8.97  ± 0.06 1.55 ± 0.27 
Table 14: pKi and hill numbers extrapolated from curve fit equations from graphs such as in 
figure 12. Data are mean ± SEM. N=3 
 
 
Figure 12 shows the competition of quipazine, a partial agonist of the 5-HT3A receptor, with 
[3H]-granisteron for the 5-HT3A receptor. There was also no difference in maximum binding 
in the absence and presence of 10 µM 5-Cl. 5-Cl also appeared to cause a leftward shift of the 
dose response curve. A small increase in quipazine binding affinity could be seen in table 14, 
although this was not significant.  
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Figure 13: Competition of (S)-zacopride for [3H]-granisetron in the absence and presence of 10 µM 5-
Cl in the h5-HT3A receptor. Error bars represent mean ± SEM. n=4 
 
 
 
  
 
Table 15: pKi and hill numbers extrapolated from curve fit equations from graphs such as in 
figure 13. Data are mean ± SEM. N=3 
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(S)-zacopride
(S)-zacopride + 10 µM 5-Cl
Concentration (M)
 pKi ± SEM Hill number ± SEM 
(S)-zacopride 9.07  ± 0.05 0.79 ± 0.08 
(S)-zacopride + 10 µM 5-Cl 9.27  ± 0.41 0.58 ± 0.12 
60 
 
Figure 13 shows the competition of (S)-zacopride, a partial agonist of the 5-HT3A receptor, 
with [3H]-granisteron. There was also no difference in maximum binding in the absence and 
presence of 10 µM 5-Cl. 5-Cl also appeared to cause a leftward shift of the dose response 
curve. The appearance of the dose response curve seems different to that of 5-HT and 
quipazine, as the curve appears flattened, as shown by a lower hill number (see table 15). 
There was also no significant increase in (S)-zacopride binding affinity for the 5-HT3A 
receptor.  
 
3.2. 5-(Trifluoromethyl)indole 
5-(trifluoromethyl)indole (5-TFMI) is a halogenated indole derivative, similar in structure to 
5-Cl. Preliminary FlexStation analyses showed 5-TFMI potentiated 5-HT-mediated (300 nM) 
calcium influx, but had no effect on intracellular calcium levels when applied alone (data not 
shown). [3H]-granisetron competition binding studies were performed to determine orthosteric 
or allosteric functions.  
 
 
Figure 14: Chemical structure of 5-(trifluoromethyl)indole. Image taken from Sigma Aldrich. 
61 
 
 
Figure 15: Lack of competition of 5-TFMI with [3H]-granisetron (orange) and lack of effect of 5-
TFMI (3 and 10 µM) on ondansetron competition with [3H]-granisetron for the h5-HT3A receptor (blue 
and black). Error bars represent mean ± SEM. n=3 
 
 
 
 
 
 
 
Table 16: pKi and hill coefficients extrapolated from curve fits in [3H]-granisetron competition 
binding with ondansetron experiments, as in figure 15. Data are mean ± SEM, n=3. 
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Ondansetron
Ondansetron + 3 µM 5-TFMI
Ondansetron + 10 µM 5-TFMI
5-TFMI
Concentration (M)
pKi ± SEM Hill number ± SEM 
Ondansetron 9.04 ± 0.03 1.06 ± 0.16 
Ondansetron + 3 µM 5-TFMI 9.01 ± 0.02 1.04 ± 0.12 
Ondansetron + 10 µM 5TFMI 8.89 ± 0.17 0.91 ± 0.07 
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In [3H]-granisetron competition studies, 5-TFMI alone showed no competition for the 5-HT3A 
receptor up to 3 µM (figure 15). At concentrations higher than 10 µM, 5-TFMI appeared to 
compete with [3H]-granisetron. When observing the effects of 5-TFMI on antagonist 
(ondansetron, figure 15, blue and black traces) binding, the curves in the presence of 3 and 10 
µM 5-TFMI showed no leftward shift of the dose-response curve. However, a decrease in 
total binding could be observed. There was no significant effect of 5-TFMI on 5-HT3A 
receptor binding affinity for ondansetron, as seen in table 16.  
 
 
Figure 16: [3H]-granisetron competition binding with 5-HT for the human 5-HT3A receptor in the 
absence and presence of 5-TFMI (3 and 10 µM). n=4-5 
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Table 17: pKi and hill coefficients extrapolated from curve fits in [3H]-granisetron competition 
binding with 5-HT experiments, as in figure 16. Data are mean ± SEM, n=4-5. Mann Whitney test, 
*p<0.05, **p<0.01 
 
 
When observing the effects of 5-TFMI on 5-HT binding (figure 16), 3 and 10 µM 5-TFMI 
significantly increased the binding affinity of the 5-HT3A receptor for 5-HT (table17), as 
shown by a leftward shift of the dose response curve. However, 5-TFMI also caused a marked 
decrease in total binding.  
 
 
 pKi ± SEM Hill number ± SEM 
5-HT 6.19 ± 0.06 2.38 ± 0.22 
5-HT + 3µM 5-TFMI 6.64 ± 0.13* 1.40 ± 0.21 
5-HT + 10µM 5-TFMI 6.89 ± 0.11** 1.06 ± 0.27* 
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Figure 17: [3H]-granisetron competition binding of quipazine for the human 5-HT3A receptor in the 
absence and presence of 5-TFMI (3 and 10 µM). n=3-4 
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Table 18: pKi and hill coefficients extrapolated from curve fits in [3H]-granisetron competition 
binding with quipazine experiments, as in figure 17. Data are mean ± SEM, n=3-4. Mann Whitney 
test, **p<0.01 
 
 
Figure 17 shows the effects of 3 and 10 µM 5-TFMI on quipazine competition binding. A 
leftward shift can be observed at both concentrations of the PAM, although the increase in 
binding affinity was only significant at 10 µM 5-TFMI (table 18). However, 5-TFMI also 
caused a marked decrease in total binding, causing maximum binding to fall to 20% of the 
maximum quipazine response in the presence of 10 µM 5-TFMI.  
 
 
 
 
 
 
 pKi ± SEM Hill number ± SEM 
Quipazine 8.48 ± 0.07 2.11 ± 0.24 
Quipazine + 3µM 5-TFMI 8.71 ± 0.08 1.68 ± 0.07 
Quipazine + 10µM 5-TFMI 9.58 ± 0.25** 1.06 ± 0.19 ** 
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Figure 18: [3H]-granisetron competition binding of (S)-zacopride in the absence and presence of 5-
TFMI (3 and 10 µM). n=2-5 
 
 
 
 
 
 
Table 19: pKi and hill coefficients extrapolated from curve fits in [3H]-granisetron competition 
binding with quipazine experiments, as in figure 17. Data are mean ± SEM, n=2-5. 
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(S)-zacopride
(S)-zacopride + 3 µM 5-TFMI
(S)-zacopride + 10 µM 5-TFMI
Concentration (M)
pKi ± SEM 
Hill 
number 
± SEM 
S-zacopride 9.35 ± 0.22 1.03 ± 0.12 
S-zacopride + 3µM 5-TFMI 9.21 ± 0.05 1.00 ± 0.08 
S-zacopride + 10µM 5-TFMI 9.96 ± 0.38 1.01 ± 0.15 
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Figure 18 shows the effects of 5-TFMI on (S)-zacopride competition binding with [3H]-
granisetron for the 5-HT3A receptor. There was no significant difference (table 19) in (S)-
zacopride binding affinity in the presence of 5-TFMI, although this could have been affected 
by the decrease in maximum binding with increasing concentrations of the PAM. 
These data show 5-TFMI appears to increase the binding affinity of full and partial agonists, 
but it also seems to affect maximum binding. This suggests 5-TFMI plays a dual role in 5-
HT3A receptor binding. 
 
3.3. 5-Bromoindazole and 5-Bromo-benzimidazole 
5-bromoindazole (5-BI) and 5-bromo-benzimidazole (5-BBI) are halogenated indole 
derivatives, differing only in the position of a nitrogen atom (see figures 19 and 20). Studying 
the pharmacological characteristics of these compounds could help understand the core 
structures necessary for allosteric modulation.  
                                                                        
 
Figure 19: 5-bromoindazole     Figure 20: 5-bromo-benzimidazole 
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Previous work in Professor Barnes’ lab showed that 5-BI stimulated calcium influx at 30 µM 
and 100 µM in the presence of 300 nM 5-HT, suggesting it could be a positive allosteric 
modulator (figure 21 left, Dr G. Gillian Grafton, Barnes lab). 5-BBI on the other hand, was 
shown to decrease intracellular calcium levels, suggesting it could be either an antagonist or a 
negative allosteric modulator (figure 21, right). [3H]-granisetron competition studies were 
performed to characterise orthosteric or allosteric properties. 
 
 
 
Figure 21: Left : Ability of 5-BI to potentiate the response evoked by 300 nM 5-HT. Right : Ability 
of 5-BBI to decrease the response evoked by 300 nM 5-HT. Error bars represent SEM. N=3. 
Unpublished data, experiments performed by Dr Gillian Grafton in the Barnes lab. 
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Figure 22: [3H]-granisetron competition binding of ondansetron (red) and 5-bromoindazole (blue) for 
the human 5-HT3A receptor. Data represent mean ± SEM. n=3. Red * show significant differences 
between data points from the first three data points (ANOVA). ** p<0.01  
 
Figure 22 shows competition radioligand binding of 5-BI compared to ondansetron as a 
control. There was little competition of 5-BI with [3H]-granisetron for the 5-HT3A receptor up 
to 10 µM. At concentrations of 30 µM and above, the total binding appears to decrease, 
suggesting competition, although the decrease was only significant at 100 µM 5-BI.  
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Figure 23: [3H]-granisetron competition binding of ondansetron (red) and 5-bromobenz-imidazole 
(green) for the human 5-HT3A receptor. Data represent mean ± SEM. n=3. Red * show significant 
differences between data points from the first three data points (ANOVA). * p<0.05 
 
Figure 23 shows competition radioligand binding of 5-BBI compared to ondansetron as a 
control. 5-BBI showed competition for the 5-HT3A receptor at concentrations above 3 µM, 
although only the data point at 100 µM 5-BBI was statistically different from baseline.  
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3.4. Construction of a Chimeric α7V2015HT3A Receptor 
Eiselé et al. (1993) developed a series of  rat/mouse chimerae possessing segments of the  α7 
nicotinic acetylcholine receptor (nAChR) and the the mouse 5-HT3A receptor. Of these 
receptors, the chimera containing the N-terminus of the rat α7 nicotinic acetylcholine receptor 
(nAChR) and the transmembrane domains and C-terminus of the mouse 5-HT3A receptor, 
joined at the 201st valine position in the receptor sequence (α7V2015HT3A), showed nAChR 
ligand binding but displayed the pharmacology of the 5-HT3A receptor. Unpublished studies 
(Grafton, Barnes lab) on the series of chimerae revealed the α7V2015HT3A chimera showed a 
lack of potentiating effects of 5-chloroindole on the activity of this chimeric receptor, 
suggesting the 5-Cl allosterc binding site is located in the N-terminus of the mouse 5-HT3A 
receptor. Due to species differences in allosteric modulation of the 5-HT3A receptor, a 
human/human chimeric receptor needed to be constructed to verify these findings.  
The original α7nAChR and 5-HT3A receptor DNA fragments were sequenced to determine the 
exact nucleic acid sequence and design primers specific to these fragments. Tables 20 and 21 
show the data obtained from using multiple primers and assembling the resulting sequences to 
form a full map of each receptor sequence.  
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      *  S  T  *  Y  D  S  L  *  A  S  L  E  A  T  M  R  C  S  P  
722   tagagtacttaatacgactcactataggctagcctcgaggccaccatgcgctgctcgccg  781 
      G  G  V  W  L  A  L  A  A  S  L  L  H  V  S  L  Q  G  E  F   
782   ggaggcgtctggctggccctggccgcgtcgctcctgcacgtgtccctgcaaggcgagttc  841 
      Q  R  K  L  Y  K  E  L  V  K  N  Y  N  P  L  E  R  P  V  A   
842   cagaggaagctttacaaggagctggtcaagaactacaatcccttggagaggcccgtggcc  901 
      N  D  S  Q  P  L  T  V  Y  F  S  L  S  L  L  Q  I  M  D  V   
902   aatgactcgcaaccactcaccgtctacttctccctgagcctcctgcagatcatggacgtg  961 
      D  E  K  N  Q  V  L  T  T  N  I  W  L  Q  M  S  W  T  D  H   
962   gatgagaagaaccaagttttaaccaccaacatttggctgcaaatgtcttggacagatcac  1021 
      Y  L  Q  W  N  V  S  E  Y  P  G  V  K  T  V  R  F  P  D  G   
1022  tatttacagtggaatgtgtcagaatatccaggggtgaagactgttcgtttcccagatggc  1081 
      Q  I  W  K  P  D  I  L  L  Y  N  S  A  D  E  R  F  D  A  T   
1082  cagatttggaaaccagacattcttctctataacagtgctgatgagcgctttgacgccaca  1141 
      F  H  T  N  V  L  V  N  S  S  G  H  C  Q  Y  L  P  P  G  I   
1142  ttccacactaacgtgttggtgaattcttctgggcattgccagtacctgcctccaggcata  1201 
      F  K  S  S  C  Y  I  D  V  R  W  F  P  F  D  V  Q  H  C  K   
1202  ttcaagagttcctgctacatcgatgtacgctggtttccctttgatgtgcagcactgcaaa  1261 
      L  K  F  G  S  W  S  Y  G  G  W  S  L  D  L  Q  M  Q  E  A   
1262  ctgaagtttgggtcctggtcttacggaggctggtccttggatctgcagatgcaggaggca  1321 
      D  I  S  G  Y  I  P  N  G  E  W  D  L  V  G  I  P  G  K  R   
1322  gatatcagtggctatatccccaatggagaatgggacctagtgggaatccccggcaagagg  1381 
      S  E  R  F  Y  E  C  C  K  E  P  Y  P  D  V  T  F  T  V  T   
1382  agtgaaaggttctatgagtgctgcaaagagccctaccccgatgtcaccttcacagtgacc  1441 
      M  R  R  R  T  L  Y  Y  G  L  N  L  L  I  P  C  V  L  I  S   
1442  atgcgccgcaggacactctactatggcctcaacctgctgatcccctgtgtgctcatctcc  1501 
      A  L  A  L  L  V  F  L  L  P  A  D  S  G  E  K  I  S  L  G   
1502  gccctcgccctgctggtgttcctgcttcctgcagattccggggagaagatttccctgggg  1561 
      I  T  V  L  L  S  L  T  V  F  M  L  L  V  A  E  I  M  P  A   
1562  ataacagtcttactctctcttaccgtcttcatgctgctcgtggctgagatcatgcccgca  1621 
      T  S  D  S  V  P  L  I  A  Q  Y  F  A  S  T  M  I  I  V  G   
1622  acatccgattcggtaccattgatagcccagtacttcgccagcaccatgatcatcgtgggc  1681 
      L  S  V  V  V  T  V  I  V  L  Q  Y  H  H  H  D  P  D  G  G   
1682  ctctcggtggtggtgacagtgatcgtgctgcagtaccaccaccacgaccccgacgggggc  1741 
      K  M  P  K  W  T  R  V  I  L  L  N  W  C  A  W  F  L  R  M   
1742  aagatgcccaagtggaccagagtcatccttctgaactggtgcgcgtggttcctgcgaatg  1801 
      K  R  P  G  E  D  K  V  R  P  A  C  Q  H  K  Q  R  R  C  S   
1802  aagaggcccggggaggacaaggtgcgcccggcctgccagcacaagcagcggcgctgcagc  1861 
      L  A  S  V  E  M  S  A  V  A  P  P  P  A  S  N  G  N  L  L   
1862  ctggccagtgtggagatgagcgccgtggccccgccgcccgccagcaacgggaacctgctg  1921 
      Y  I  G  F  R  G  L  D  G  V  H  C  V  P  T  P  D  S  G  V   
1922  tacatcggcttccgcggcctggacggcgtgcactgtgtcccgacccccgactctggggta  1981 
      V  C  G  R  M  A  C  S  P  T  H  D  E  H  L  L  H  G  G  Q   
1982  gtgtgtggccgcatggcctgctcccccacgcacgatgagcacctcctgcacggcgggcaa  2041 
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      P  P  E  G  D  P  D  L  A  K  I  L  E  E  V  R  Y  I  A  N   
2042  ccccccgagggggacccggacttggccaagatcctggaggaggtccgctacattgccaac  2101 
      R  F  R  C  Q  D  E  S  E  A  V  C  S  E  W  K  F  A  A  C   
2102  cgcttccgctgccaggacgaaagcgaggcggtctgcagcgagtggaagttcgccgcctgt  2161 
      V  V  D  R  L  C  L  M  A  F  S  V  F  T  I  I  C  T  I  G   
2162  gtggtggaccgcctgtgcctcatggccttctcggtcttcaccatcatctgcaccatcggc  2221 
      I  L  M  S  A  P  N  F  V  E  A  V  S  K  D  F  A  *  A  A   
2222  atcctgatgtcggctcccaacttcgtggaggccgtgtccaaagactttgcgtaagcggcc  2281 
      A  S  L  *  *  G  L  M  L  R  A  D  M  I  R  Y  I  D  E  F   
2282  gcttccctttagtgagggttaatgcttcgagcagacatgataagatacattgatgagttt  2341 
Table 20: a7nACh receptor nucleic acid sequence with overlaid translated protein sequence. 
Restriction enzyme cleavage sites are marked in green (NotI at the 5’ end and XhoI at the 3’ end) in 
the nucleic acid sequence. In the protein sequence, the signalling peptide sequence is marked in blue 
and * mark stop codons. The conserved valine for the construction of the chimera and corresponding 
codon (position 754-756) are marked in red.  
 
 
      N  *  Y  D  S  L  *  G  D  P  S  W  L  V  K  L  G  T  E  L   
2     aattaatacgactcactatagggagacccaagctggctagttaagcttggtaccgagctc  61 
      G  S  P  G  L  Q  E  F  R  G  H  E  R  Q  A  G  W  D  M  R   
62    ggatcccccgggctgcaggaattccggggccacgagaggcaggctggctgggacatgagg  121 
      L  A  E  G  R  Q  A  G  P  W  W  A  S  P  *  A  L  G  G  T   
122   ttggcagagggcaggcaagctggcccttggtgggcctcgccctgagcactcggaggcact  181 
      P  M  L  G  K  L  A  M  L  L  W  V  Q  Q  A  L  L  A  L  L   
182   cctatgcttggaaagctcgctatgctgctgtgggtccagcaggcgctgctcgccttgctc  241 
      L  P  T  L  L  A  Q  G  E  A  R  R  S  R  E  Q  K  L  I  S   
242   ctccccacactcctggcacagggagaagccaggaggagccgagaacaaaaactcatctca  301 
      E  E  D  L  N  T  T  R  P  A  L  L  R  L  S  D  Y  L  L  T   
302   gaagaggatctgaacaccaccaggcccgctctgctgaggctgtcggattaccttttgacc  361 
      N  Y  R  K  G  V  R  P  V  R  D  W  R  K  P  T  T  V  S  I   
362   aactacaggaagggtgtgcgccccgtgagggactggaggaagccaaccaccgtatccatt  421 
      D  V  I  V  Y  A  I  L  N  V  D  E  K  N  Q  V  L  T  T  Y   
422   gacgtcattgtctatgccatcctcaacgtggatgagaagaatcaggtgctgaccacctac  481 
      I  W  Y  R  Q  Y  W  T  D  E  F  L  Q  W  N  P  E  D  F  D   
482   atctggtaccggcagtactggactgatgagtttctccagtggaaccctgaggactttgac  541 
      N  I  T  K  L  S  I  P  T  D  S  I  W  V  P  D  I  L  I  N   
542   aacatcaccaagttgtccatccccacggacagcatctgggtcccggacattctcatcaat  601 
      E  F  V  D  V  G  K  S  P  N  I  P  Y  V  Y  I  R  H  Q  G   
602   gagttcgtggatgtggggaagtctccaaatatcccgtacgtgtatattcggcatcaaggc  661 
      E  V  Q  N  Y  K  P  L  Q  V  V  T  A  C  S  L  D  I  Y  N   
662   gaagttcagaactacaagccccttcaggtggtgactgcctgtagcctcgacatctacaac  721 
      F  P  F  D  V  Q  N  C  S  L  T  F  T  S  W  L  H  T  I  Q   
722   ttccccttcgatgtccagaactgctcgctgaccttcaccagttggctgcacaccatccag  781 
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      D  I  N  I  S  L  W  R  L  P  E  K  V  K  S  D  R  S  V  F   
782   gacatcaacatctctttgtggcgcttgccagaaaaggtgaaatccgacaggagtgtcttc  841 
      M  N  Q  G  E  W  E  L  L  G  V  L  P  Y  F  R  E  F  S  M   
842   atgaaccagggagagtgggagttgctgggggtgctgccctactttcgggagttcagcatg  901 
      E  S  S  N  Y  Y  A  E  M  K  F  Y  V  V  I  R  R  R  P  L   
902   gaaagcagtaactactatgcagaaatgaagttctatgtggtcatccgccggcggcccctc  961 
      F  Y  V  V  S  L  L  L  P  S  I  F  L  M  V  M  D  I  V  G   
962   ttctatgtggtcagcctgctactgcccagcatcttcctcatggtcatggacatcgtgggc  1021 
      F  Y  L  P  P  N  S  G  E  R  V  S  F  K  I  T  L  L  L  G   
1022  ttctacctgccccccaacagtggcgagagggtctctttcaaaattacactcctcctgggc  1081 
      Y  S  V  F  L  I  I  V  S  D  T  L  P  A  T  A  I  G  T  P   
1082  tactcggtcttcctgatcatcgtttctgacacgctgccggccactgccatcggcactcct  1141 
      L  I  G  V  Y  F  V  V  C  M  A  L  L  V  I  S  L  A  E  T   
1142  ctcattggtgtctactttgtggtgtgcatggctctgctggtgataagtttggccgagacc  1201 
      I  F  I  V  R  L  V  H  K  Q  D  L  Q  Q  P  V  P  A  W  L   
1202  atcttcattgtgcggctggtgcacaagcaagacctgcagcagcccgtgcctgcttggctg  1261 
      R  H  L  V  L  E  R  I  A  W  L  L  C  L  R  E  Q  S  T  S   
1262  cgtcacctggttctggagagaatcgcctggctactttgcctgagggagcagtcaacttcc  1321 
      Q  R  P  P  A  T  S  Q  A  T  K  T  D  D  C  S  A  M  G  N   
1322  cagaggcccccagccacctcccaagccaccaagactgatgactgctcagccatgggaaac  1381 
      H  C  S  H  M  G  G  P  Q  D  F  E  K  S  P  R  D  R  C  S   
1382  cactgcagccacatgggaggaccccaggacttcgagaagagcccgagggacagatgtagc  1441 
      P  P  P  P  P  R  E  A  S  L  A  V  C  G  L  L  Q  E  L  S   
1442  cctcccccaccacctcgggaggcctcgctggcggtgtgtgggctgctgcaggagctgtcc  1501 
      S  I  R  Q  F  L  E  K  R  D  E  I  R  E  V  A  R  D  W  L   
1502  tccatccggcaattcctggaaaagcgggatgagatccgagaggtggcccgagactggctg  1561 
      R  V  G  S  V  L  D  K  L  L  F  H  I  Y  L  L  A  V  L  A   
1562  cgcgtgggctccgtgctggacaagctgctattccacatttacctgctagcggtgctggcc  1621 
      Y  S  I  T  L  V  M  L  W  S  I  W  Q  Y  A  *  V  G  T  A   
1622  tacagcatcaccctggttatgctctggtccatctggcagtacgcttgagtgggtacagcc  1681 
      Q  W  R  R  G  Y  S  P  G  *  V  G  T  E  D  F  C  L  G  P   
1682  cagtggaggagggggtacagtcctggttaggtggggacagaggatttctgcttaggcccc  1741 
      S  G  P  R  E  C  Q  G  H  F  Q  D  T  D  K  V  P  C  P  V   
1742  tcaggacccagggaatgccagggacattttcaagacacagacaaagtcccgtgccctgtt  1801 
      S  N  A  N  S  S  Q  Q  S  Q  A  K  V  *  T  L  P  P  K  T   
1802  tccaatgccaattcatctcagcaatcacaagccaaggtctgaacccttccaccaaaaact  1861 
      G  C  S  R  P  L  H  P  C  P  T  P  S  S  S  P  W  L  *  N   
1862  gggtgttcaaggcccttacacccttgtcccacccccagcagctcaccatggctttaaaac  1921 
      M  L  S  *  I  R  R  N  S  G  T  P  *  V  H  S  S  C  G  L   
1922  atgctctcttagatcaggagaaactcgggcactccctaagtccactctagttgtggactt  1981 
      F  P  I  D  P  H  L  N  K  G  L  W  N  S  I  S  S  L  S  I   
1982  ttccccattgaccctcacctgaataagggactttggaattcgatatcaagcttatcgata  2041 
      P  S  T  S  S  M  H  L  E  G  P 
2042  ccgtcgacctcgagcatgcatctagagggccct  2074 
Table 21: 5-HT3A receptor nucleic acid sequence with overlaid translated protein sequence. 
Restriction enzyme cleavage sites are marked in green (BamHI at the 5’ end and XbaI at the 3’ end) in 
the nucleic acid sequence. In the protein sequence, the signalling peptide sequence is marked in blue 
and * mark stop codons. The conserved valine for the construction of the chimera and corresponding 
codon (position 941-943) are marked in red at positions. 
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The first round of overlap extension PCR was successful in obtaining the α7nAChR and 5-
HT3A receptor megaprimers (expected bands of 721 and 1126 bp respectively), shown in 
figure 24. The second round of PCR using the megaprimers as templates for each other was 
however unsuccessful in producing a full length chimera of 1836 bp, as no band was visible 
in an agarose gel electrophoresis. Due to the lack of a chimeric receptor with this method, 
another method (introducing a common restriction site to ligate sticky ends) was attempted in 
parallel to optimise production.  
 
 
Figure 24: Products of first round of overlap extension PCR, the α7 nAChR N-terminus fragment with 
3’ 5-HT3A overhang and the 5-HT3A C-terminal fragment with 5’ α7 nAChR overhang.  
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Restriction endonuclease digest of the plasmid vector containing the 5-HT3A DNA with MreI 
and XbaI was successful in obtaining the correct size fragment (1126 base pairs, see 
figure 25). PCR of the α7nAChR DNA to introduce the MreI restriction site appeared to be 
successful as it rendered a band of the correct size (721 bp, see figure 26). The α7nAChR 
fragment was then excised and digested with restriction enzymes BamHI and MreI. The 
ligation of these α7nAChR and 5-HT3A fragments appeared to succeed as a band of the 
correct size (1847 bp, see figure 27) was visible, although the negative control also produced 
a band of the same size, suggesting contamination. Subsequent amplification of the potential 
chimeric fragment with primers α7 FF and 3A RF did not yield any further products and DNA 
sequencing failed to reveal a chimeric sequence, suggesting the band was produced as a result 
of contamination.  
                                      
Figure 25: Double digest of pcDNA3.1-5-HT3A with MreI/XbaI 
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Figure 26: PCR product of α7nAChR with MreI site inserted. 
 
Figure 27: Ligation of α7 nAChR and 5-HT3A fragment 
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CHAPTER 4: DISCUSSION 
Experiments studying 5-chloroindole’s impact upon the human 5-HT3A receptor suggest it is a 
positive allosteric modulator, although results were not significant. Data published by 
Newman et al. (2013) show it is a potent positive allosteric modulator of the human 5-HT3A 
receptor and it has served as a useful tool for characterising allosteric binding and developing 
novel compounds. Due to time constraints, it was not possible to complete further 
experiments, which could have increased the significance of the results.  
5-(trifluoromethyl)indole, a halogenated indole derivative with a similar structure to 5-
chloroindole, showed allosteric binding by potentiating the 5-HT response in intracellular 
calcium studies. Initial radioligand binding studies revealed allosteric binding due to the lack 
of competition with [3H]-granisetron for the orthosteric binding site at relevant 
concentrations. [3H]-granisetron competition binding studies in the presence of agonists 
showed positive allosteric modulation of the 5-HT3A receptor by potentiating full and partial 
agonist responses and increasing their affinities for the 5-HT3A receptor. These experiments 
however also revealed orthosteric binding due to 5-TFMI competing with [3H]-granisetron 
and decreased the total binding of the drugs, which is contradictory to the initial results 
showing a lack of orthosteric binding. One possible explanation could be 5-TFMI binds to 
part of the orthosteric binding site and part of the allosteric binding site simultaneously. If this 
is the case, this would suggest the allosteric binding site is in close proximity to the 
orthosteric binding site in the N-terminus. Another hypothesis could be that 5-TFMI only 
binds to the orthosteric binding site, but causes the contributing loops to fold differently, by 
either stabilising the binding pocket formed by loops A, B, D and E, or to increase loop C 
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contraction around the agonists. This would result in agonists binding more preferentially to 
the same or another othosteric binding site on the receptor, or binding for longer durations and 
thus potentiating the agonists’ responses. This is an interesting concept as it would suggest 
there are compounds which bind to the orthosteric site and have no action alone but increase 
the binding affinities of other drugs to the orthosteric site to increase the receptor response.  
5-bromoindazole and 5-bromobenz-imidazole were interesting to study for their structure-
activity relationships. They have shown that the structure of a compound is vital to its 
function and very small changes to the structure of a halogenated indole can turn a positive 
allosteric modulator (5-BI) into a negative allosteric modulator or antagonist.  
 In addition to studying the pharmacology of the allosteric binding site, locating the allosteric 
binding site is also important for understanding allosteric modulation. Previous studies 
(Corringer et al. (1998) and  Kracun et al. (2008)) studying  a series of rat/mouse α7nAChR/5-
HT3A subunit chimeras showed that the α7V2015-HT3A chimera, with the N-terminus of the 
α7nAChR and the rest of the receptor being 5-HT3A, would bind acetylcholine, but retained 
the pharmacology of the 5-HT3A receptor. This was an interesting receptor to study for ligand 
binding properties. Further unpublished studies (Grafton, G., personal communication) on the 
same chimeric receptors revealed that of the range of chimeras, the response evoked by 
acetylcholine in the α7V2015-HT3A chimera was not potentiated by 5-chloroindole. This would 
suggest the allosteric binding site of the 5-HT3A receptor was in the N-terminus, due to 
elimination of allosteric activity in the chimera. However, this chimeric receptor was a 
rat/mouse chimera, and as previously discussed, there are species differences (Hoyer and 
Middlemiss, 1989) in allosteric modulation of the 5-HT3 receptor, thus requiring the 
construction of a human/human chimera  to support these results.  
80 
 
I attempted to replicate the methods of Bertrand et al. (2008) using overlap extension PCR, 
but the overhangs produced appeared to be too short to prime the complementary strand. I 
attempted to elongate the primers, in order to produce a larger overhang, but to no avail. I did 
not use identical primers to Bertrand et al. (2008) due to the different restriction enzymes 
needed to insert the chimeric receptor into a plasmid vector. The PCR products I obtained had 
small portions of plasmid sequence due to the location of the restriction enzymes and perhaps 
this prevented annealing of primers or overhangs.  In parallel, I attempted to cleave the 
sequence at the V201 region with MreI and ligate the digested fragments together. Digestion 
of the 5-HT3A receptor fragment was successful but the MreI restriction site needed to be 
introduced into the α7nAChR sequence by PCR, therefore it is possible this PCR was 
unsuccessful as the primer was not fully complementary to the α7nAChR sequence. I believe 
if more time had been available, the overlap extension PCR would have succeeded as I 
optimised parameters.  
Studying the structure-activity relationship of allosteric modulators of the human 5-HT3A 
receptor will allow us to determine the pharmacophore, the core structure of a compound, and 
then to make smaller alterations in the structure to create potent allosteric modulators. The 
aim would be to develop negative allosteric modulators which will bind with high affinity to 
the 5-HT3A receptor and decrease intrinsic activity without total blockade. A negative 
allosteric modulator of the 5-HT3A receptor could have multiple therapeutic uses both 
centrally and peripherally. Activation of 5-HT3 receptors centrally causes pro-emetic and 
anxiogenic effects and peripherally, stimulates peristalsis in IBS-D patients. Decreasing the 
activity of the 5-HT3 receptor would therefore be useful in improving the treatment of 
symptoms without the unpleasant side effects observed during full blockade using 
antagonists. Determining the location and structure of the allosteric binding site could help in 
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developing therapeutically relevant compounds. However, allosteric modulators could be 
stabilising a conformational state not usually seen in the resting state of the receptor, therefore 
studying the structure of the receptor when bound to an allosteric modulator could also 
improve the development of agonists and antagonists with higher binding affinity. 
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CHAPTER 5: FURTHER WORK 
I have outlined the importance of structure-activity relationship in this study on halogenated 
indole derivatives. Further work is needed on determining which structures are important for 
binding to the allosteric binding site, which structures determine positive allosteric 
modulation and which ones determine negative allosteric modulation. PAMs have proved 
useful for studying the pharmacology of the binding site. 5-chloroindole is a potent PAM, but 
5-TFMI appears to demonstrate both orthosteric and allosteric properties. One way of 
determining whether 5-TFMI does bind to the orthosteric binding site would be to study [3H]-
granisetron competition binding of 5-TFMI (as in figure 16, yellow data points) in the 
absence and presence of a low concentration of 5-HT. If the total level of binding is decreased 
by 5-HT, this would mean 5-HT is competing with 5-TFMI for the orthosteric binding site. 
The functions of 5-BI and 5-BBI are determined by the position of a nitrogen atom in their 
structure. The grouping of all this information and further studies will ultimately define the 
core structure of an allosteric modulator of the human 5-HT3A receptor, which will bind with 
high affinity to the site. This will then aid in designing negative allosteric modulators with 
potential therapeutic use.  
Constructing the human/human α7V2015-HT3A chimera is equally essential in supporting the 
data found in the rat/mouse chimera. This would confirm findings that the allosteric binding 
site is located in the N-terminus of the 5-HT3A receptor and thus mutants or knock-outs of 
smaller sections of the N-terminus could be constructed to determine the precise residues 
involved in the allosteric binding site.  
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Due to the recent success in obtaining the crystal structure of the mouse 5-HT3A receptor, this 
will remarkably help in progressing with studying the allosteric binding site. An interesting 
experiment to conduct would be a crystal soak, where the protein is crystallised and then 
soaked in the ligand, which will result in a ligand-protein interaction stable enough for 
visualisation (Hassell et al., 2007). However,  Hassaine et al. (2014) discuss the fact that the 
co-crystallisation molecules VHH15 bind to parts of the ligand binding domain and inhibit 5-
HT induced currents in electrophysiological experiments. This could therefore hinder the 
binding of some compounds to the orthosteric binding site but if 5-chloroindole is a PAM 
which binds solely to the allosteric binding site, this binding interaction could still be studied.  
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